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"I heard that scientists are growing 
human organs in lab dishes." 
"Is this true?"
ABSTRACT 
Advances  in  stem  cell  biology  have  challenged  the  notion  that  infarcted  myocardium  is 
irreparable. The pluripotent ability of stem cells to differentiate into specialized cell lines began to 
garner intense interest within cardiology when it was shown in animal models that intramyocardial 
injection of bone marrow stem cells (MSCs), or the mobilization of bone marrow stem cells with 
spontaneous homing to myocardium, could improve  cardiac  function and survival  after  induced 
myocardial infarction (MI) [1, 2]. Furthermore, the existence of stem cells in myocardium has been 
identified in animal heart  [3, 4], and intense research is under way in an attempt to clarify their 
potential clinical application for patients with myocardial infarction. To date, in order to identify the 
best one, different kinds of stem cells have been studied; these have been derived from embryo or 
adult  tissues  (i.e.  bone marrow,  heart,  peripheral  blood etc.).  Currently,  three different  biologic 
therapies  for  cardiovascular  diseases  are  under investigation:  cell  therapy,  gene therapy and the 
more recent “tissue-engineering” therapy .
During  my Ph.D.  course,  first  I  focalised  my study on  the  isolation  and characterization  of 
Cardiac Stem Cells (CSCs) in wild-type and transgenic mice and for this purpose I attended, for 
more than one year, the  Cardiovascular Research Institute of  the New York Medical College, in 
Valhalla  (NY,  USA)  under  the  direction  of  Doctor  Piero  Anversa.  During  this  period  I  learnt 
different  Immunohistochemical  and  Biomolecular  techniques,   useful  for  investigating  the 
regenerative potential of stem cells. 
Then, during the next two years, I studied the new approach of cardiac regenerative medicine 
based on  “tissue-engineering”  in order to investigate  a new strategy to regenerate  the infarcted 
myocardium.  Tissue-engineering is a promising approach that makes possible the creation of new 
functional tissue to replace lost or failing tissue. This new discipline combines isolated functioning 
cells and biodegradable 3-dimensional (3D) polymeric scaffolds. The scaffold temporarily provides 
the biomechanical support for the cells until they produce their own extracellular matrix. Because 
tissue-engineering  constructs  contain  living  cells,  they  may  have  the  potential  for  growth  and 
cellular self-repair and remodeling. In the present study, I examined whether the tissue-engineering 
strategy within hyaluron-based scaffolds would result in the formation of alternative cardiac tissue 
that could replace the scar and improve cardiac function after MI in syngeneic heterotopic rat hearts. 
Rat hearts were explanted, subjected to left coronary descending artery occlusion, and then grafted 
into the abdomen (aorta-aorta anastomosis) of receiving syngeneic rat. After 2 weeks, a pouch of 3 
mm2 was made in the thickness of the ventricular wall at the level of the post-infarction scar. The 
hyaluronic  scaffold,  previously engineered for 3 weeks with rat  MSCs, was introduced into the 
pouch and the myocardial edges sutured with few stitches. Two weeks later we evaluated the cardiac 
function by M-Mode echocardiography and the myocardial morphology by microscope analysis.
We chose bone marrow-derived  mensenchymal  stem cells  (MSCs) because they have shown 
great signaling and regenerative properties when delivered to heart tissue following a myocardial 
infarction (MI). However, while the object of cell transplantation is to improve ventricular function, 
cardiac cell  transplantation has had limited success because of poor graft  viability and low cell 
retention, that’s why we decided to combine MSCs with a biopolimeric scaffold. 
At the end of the experiments we observed that the hyaluronan fibres had not been substantially 
degraded 2 weeks after heart-transplantation. Most MSCs had migrated to the surrounding infarcted 
area where they were especially found close to small-sized vessels. Scar tissue was moderated in the 
engrafted region and the thickness of the corresponding ventricular wall was comparable to that of 
the non-infarcted remote area. Also, the left ventricular shortening fraction, evaluated by M-Mode 
echocardiography,  was  found a  little  bit  increased  when compared  to  that  measured  just  before 
construct transplantation. Therefore, this study suggests that post-infarction myocardial remodelling 
can be favourably affected by the grafting of MSCs delivered through a hyaluron-based scaffold
1. Orlic D, Kajstura J, Chimenti S, Limana F, Jakoniuk I, Quaini F, et al.  Mobilized bone marrow 
cells  repair  the  infarcted  heart,  improving  function  and  survival.  Proc  Natl  Acad  Sci U  S  A 
2001;98(18):10344-9
2.  Orlic  D,  Kajstura  J,  Chimenti  S,  Jakoniuk I,  Anderson SM, Li  B,  et  al.  Bone marrow cells 
regenerate infracted myocardium. Nature 2001;410:701-5
3.  Beltrami A, Barlucchi L, Torella D, Baker M, Limana F,  Chimenti  S,  Kasahara H, Rota M, 
Musso  E,  Urbanek  K  Adult  cardiac  stem  cells  are  multipotent  and  support  myocardial 
regeneration.bCell. 2003 Sep 19;114(6):763-76
4. Nadal-Ginard B , Anvera P, Kajstura J, Leri A Cardiac stem cells and myocardial regeneration. 
Novartis Found Symp 2005; 265: 142-54
4
TABLE OF CONTENTS
LIST OF ABBREVIATION                                                                                                               6
INTRODUCTION                                                                                                                               8
1. Heart Failure                                                                                                                            9
2. Cardiac regenerative medicine: the Stem Cells Therapy                                                      11
3. Stem Cells                                                                                                                                12
3.1 Cardiac Stem Cell                                                                                                             17
3.2 Bone Marrow Mesenchymal Stem cells                                                                           20
3.2.1 Bone Marrow-MSC and cardiac repairing                                                                  24
4. Cell delivery in cardiac stem cell therapy                                                                              26
5. Tissue-engineering: a new approach for cell delivery in cardiac regenerative medicine   30
5.1 Materials as scaffolds for cells transplantation in cardiac tissue-engineering             33
6. Strategies, challegenges and further directions                                                                    37
EXPERIMENTAL SECTION                                                                                                         40
Aim of the study                                                                                                                            41
Materials&Methods                                                                                                                      42
Results                                                                                                                                           53
Discussion                                                                                                                                     65
Conclusion                                                                                                                                    68
APPENDIX                                                                                                                                        69
REFERENCES                                                                                                                                  80
5
LIST OF ABBREVIATION
CCT = Cardiac Cell Therapy
MI = Myocardial Infarction
ICM = Inner Cell Mass
ES = Embrionic Stem cells
HSCs = Hematopoietic Stem Cells
SP cells = Side Population cells
CSCs = Cardiac Stem Cells
MSCs = Mesenchymal Stem Cells or Mesenchymal Stromal Cells
BM-MSCs or BMSCs = Bone Marrow derived Mesenchymal Stem or Stromal Cells
MAPC = Multipotent Adult Progenitor
TCSC = Tissue Committed Stem Cells
CFU = Colony Forming Units
FACS = Fluorescent-Activated Cell Sorting
SDF-1 = Stromal cell-Derived Factor-1
GFP = Green Fluorescent Protein
VEGF = Vascular Endothelial Growth Factor
HGF = Hepatocyte Growth Factor
AM = AdrenoMedullin
IGF-1 = Insulin Growth Factor-1
MCP-1 = Monocyte Chemeattractant Protein-1
MR and MRI = Magnetic Resonance and Magnetic Resonce Imaging 
ECM = Extra Cellular Matrix
PLA = PolyLactic Acid
PGA = PolyGlicolic Acid
PCL = PolyCaproLactone
GAGs = GlycosAminoGlycans
PLGA = PolyLactic-co-Glycolic Acid
PIPAAm = poly(N-isopropylacrylamide)
PVDF = Poly(Vinylidene difluoride)
HA = Hyaluronic Acid
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ICAM-1 = IntraCellular Adhesion Molecule-1
HASs = Hyaluronic Acid Synthases
HYALs = Hyaluronidases
HABPs = Hyaluronic Acid Binding Proteins
RHAMM = Receptor for Hyaluronan Mediated Mobility expressed protein
LYVE-1 = Lymphatic Vessel Endothelial Hyaluronan Receptor-1
COX-2 = Cycloxygenase-2
HYAFF® 11 = Hyaluronan biopolymer produced by Fidia Advanced Biopolymer
BSA = Bovine Serum Albumin
FBS = Fetal Bovine Serum 
PBS = Phosphate Buffered Salin 
DAPI = 4',6-Diamidino-2-Phenylindole
SEM = Scanning Electron Microscopy
TEM = Transmission Electron Microscopy
CFDA-SE = CarboxyFluorescein DiAcetate Succinimydil Ester
MTT = (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
LM = Light Microscopy
BrdU = 5- Bromo- 2’ DeoxyUridine
LAD = Left Artery Discendent
FS = Fractional Shortening
LVDd or LVDs = Left Ventricular Diameter in diastole or systole
H&E = Hematoxylin and Eosin
cTnI = cardiac Troponin I
MP = Phagocyte Marker
CM = cardiomyocytes
ODC =Ornithine decarboxylase
α-MHC = α-Myosin Haevy Chain
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INTRODUCTION
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1. Heart failure
Heart failure is a major cardiovascular health problem worldwide.  Despite advances in medical 
therapy and coronary revascularization strategies, ischemic heart disease remains the leading cause 
of congestive heart failure and cardiovascular mortality in industrialized countries. For example in 
USA about 5.2 million patients have heart failure, and the lifetime risk of developing chronic heart 
failure for both men and women is 1 in 5 [1] . Coronary artery disease is the most common cause of 
heart  failure,  followed  by  idiopathic  dilated  cardiomyopathy  and  valvular  heart  disease  [2,  3]. 
Obstruction of coronary artery leads to myocardial infarction (heart attack) with associated necrosis 
of the myocardium, followed by infiltration of inflammatory cells. Then a scar forms, leading to the 
loss  of  cardiac  function,  ventricular  remodelling  and  progressive  dysfunction,  and,  finally, 
congestive heart failure [4-6]. 
Current therapy of heart failure is limited to the treatment of already established disease and is 
predominantly pharmacological, aiming primarily to inhibit the neurohormonal axis that results in 
excessive  cardiac  activation  through  angiotensin-  or  norepinephrine-dependent  pathways.  For 
patients with end-stage heart failure treatment options are extremely limited, with fewer than 3,000 
being offered cardiac transplants annually due to the severely limited supply of donor organs [7, 8], 
and implantable left ventricular assist devices being expensive, not proven for long-term use, and 
associated  with  significant  complications  [9-11].  Therefore,  there  is  a  need  to  develop  more 
effective, less invasive therapeutic strategies for heart failure. Because the self-renewal capacity of 
adult cardiomyocytes is limited, the development of strategies to regenerate damaged myocardium 
and  improve  heart  function  represents  a  major  challenge.  Analysis  of  cardiac  myocyte  growth 
during  early  mammalian  development  indicates  that  cardiac  myocyte  DNA  synthesis  occurs 
primarily in utero, with proliferating cells decreasing from 33% at midgestation to 2% at birth [12]. 
While  ventricular  karyokinesis  and  cytokinesis  are  coupled  during  fetal  growth,  resulting  in 
increases in mononucleated cardiac myocytes, karyokinesis occurs in the absence of cytokinesis for 
a  transient  period during the postnatal  period,  resulting  in  binucleation  of  ventricular  myocytes 
without  an  overall  increase  in  cell  number.  A  similar  dissociation  between  karyokinesis  and 
cytokinesis characterizes the primary adult mammalian cardiac response to ischemia, resulting in 
myocyte  hypertrophy  and  increase  in  nuclear  ploidy  rather  than  myocyte  hyperplasia  [13,  14]. 
Throughout life a mixture of young and old cells is present in the normal myocardium. Although 
most myocytes seem to be terminally differentiated, there is a fraction of younger myocytes (15–
20%) that retains the capacity to replicate [15]. 
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Moreover, recent observations suggest that some human ventricular cardiomyocytes also have the 
capacity to proliferate and regenerate in response to ischemic injury [16, 17]. The dividing myocytes 
can be identified on the basis of immunohistochemical staining of proliferating nuclear structures 
such as  Ki67 and cell  surface expression of  specific  surface  markers,  including  c-kit  (CD117). 
Whether  these  cells  are  derived  from  a  resident  pool  of  cardiomyocyte  stem  cells  or  from  a 
renewable  source  of  circulating  bone  marrow  derived  stem  cells  that  home  to  the  damaged 
myocardium remains to be determined. More importantly, the signals required for homing, in situ 
expansion, and differentiation of these cells are at present unknown. Gaining and understanding of 
these issues would open the possibility of manipulating the biology of endogenous cardiomyocytes 
to augment the healing process after myocardial ischemia [18]. 
Over the past several years a number of studies have suggested that stem cells can be used to 
generate  cardiomyocytes  and endothelial  cells  ex vivo and  in  vivo [19-23]  and so Cardiac  Cell 
Therapy (CCT) should represent a new approach to replacing damaged myocardium. 
The cell therapy for heart failure could has the potential to restore cardiac function by inducing 
neovascularization,  and  regenerating  and  protecting  cardiomyocytes  [4]. Replacement  and 
regeneration of functional cardiac muscle after an ischemic insult to the heart could be achieved by 
either stimulating proliferation of endogenous mature cardiomyocytes or resident cardiac stem cells 
or  by  implanting  exogenous  donor-derived  or  allogeneic  cardiomyocytes.  The  newly  formed 
cardiomyocytes must integrate precisely into the existing myocardial wall to augment contractile 
function of the residual myocardium in a synchronized manner and avoid alterations in the electrical 
conduction  and  syncytial  contraction  of  the  heart,  potentially  resulting  in  life-threatening 
consequences.  In  addition,  whatever  the  source  of  the  cells  used,  it  is  likely  that  concurrent 
myocardial revascularization must also occur to ensure viability of the repaired region and prevent 
further scar tissue formation [18].
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2. Cardiac regenerative medicine: the Stem Cells Therapy
It’s  widely agreed  that  regenerative  capacity  of  human  myocardium is  grossly inadequate  to 
compensate for the severe loss of heart muscle presented by catastrophic myocardial infarction or 
other myocardial diseases. 
The ideal therapy for heart failure would have the following activities; it would minimize loss of 
cardiomyocytes by reducing cell death, promote return of stunned and hibernating myocardium to 
normal function, stimulate revascularization of the ischemic region by enhancing angiogenesis, and 
regenerate  viable  cardiomyocytes  to replace those lost to the initial  ischemia thereby preserving 
contractile function and reducing the opportunity for scarring [4]. Recent advances in biotechnology 
and in the understanding of tissue regeneration have allowed development of novel therapeutics with 
the potential to approximate this ideal: the stem cell therapy. 
Cardiac stem cell therapy involves delivering a variety of cells into hearts following myocardial 
infarction or chronic cardiomyopathy [Fig.1]. Suitable sources of cells for cardiac transplant will 
depend on the types of diseases to be treated. For acute myocardial infarction, a cell that reduces 
myocardial necrosis and augments vascular blood flow will be desirable. For heart failure, cells that 
replace  or  promote  myogenesis,  reverse  apoptopic  mechanisms  and  reactivate  dormant  cell 
processes will be useful. 
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Figure 1.  Stem cells  as  applied for  the  treatment  of  myocardial  infarcts.  The main purpose of  stem cell  therapies  for  the 
treatment of myocardial infarcts is the prevention and or regeneration of dying muscle. A variety of cell types have been used for  
such a treatment. These cells include  skeletal myoblasts, bone marrow-MSCs, cardiac resident stem cells, and embryonic stem 
cells including their differentiated progeny (Figure from Christoforou N and Gearhant JD, 2007).
Stem cells might play a role in cardiac repairing becoming a specialized cell. One important type 
of cell that can be developed is the cardiomyocyte, the heart muscle cell that contracts to eject the 
blood out of the heart's main pumping chamber (the ventricle). Two other cell types are important to 
a properly functioning heart are the vascular endothelial cell, which forms the inner lining of new 
blood vessels, and the smooth muscle cell, which forms the wall of blood vessels. The heart has a 
large demand for blood flow, and these specialized cells are important for developing a new network 
of arteries to bring nutrients and oxygen to the cardiomyocytes after a heart has been damaged. The 
potential capability of both embryonic and adult stem cells to develop into these cells types in the 
damaged heart is now being explored as part of a strategy to restore heart function to people who 
have had heart attacks or have congestive heart failure.
3. Stem Cells
In  the  last  few years,  great  emphasis  has  been  placed  on  the  isolation,  characterization  and 
potential therapeutic uses of stem cells. Stem cells are defined as cells capable of both self-renewal 
and commitment to differentiation into one or more mature cell types. However different types of 
stem cells can be distinguished on the basis of their developmental potential.
The real totipotent stem cells are the fertilized oocyte (the zygote) and its descendants of the first 
two divisions. These cells are indeed able to form the embryo and the trophoblasts of the placenta. 
After about 4 days,  these totipotent cells begin to specialize,  forming a hollow ball of cells,  the 
blastocyst, and a cluster of cells called the inner cell mass (ICM) from which the embryo develops. 
The ICM cells are considered to be pluripotent, namely able to differentiate into almost all cells that 
arise from the three germ layers, but they are unable to give rise to the placenta and supporting 
tissues. ICM cells can be maintained in culture and the cell lines derived, known as embryonic stem 
(ES)  cells,  are  also  considered  to  be  pluripotential  [Fig.2].  In  the  adult,  most  tissues  have 
multipotential stem cells, defined a cells capable of producing a limited range of differentiated cell 
lineages  appropriate  to  their  location.  Also  adult  stem cells  are  heterogeneous  with  respect  to 
developmental potential. For example, small intestinal stem cells can produce all four indigenous 
lineages (Paneth, goblet, absorptive columnar, and enteroendocrine), while central nervous system 
(CNS) stem cells have tri-lineage potential, giving rise to neurons, oligodendrocytes, and astrocytes. 
At the bottom of  the stem cell hierarchy are unipotential  stem cells,  capable of generating one 
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specific cell type. Examples are epidermal stem cells in the basal layer that produce only keratinized 
squames and certain adult hepatocytes that have long-term repopulating ability [24]. 
Tissue-specific  stem cells  appear  to  be present  in  most  organs  of  the  body,  and share some 
common properties:
(1) Stem cells are a self-maintaining population. 
This is achieved if, on average, each stem cell division gives rise to one replacing stem cell and 
one transit-amplifying cell (asymmetrical division). Equally well, stem cell numbers would remain 
constant if only symmetrical divisions occurred, provided that each time a stem cell gave rise to two 
daughter transit amplifying cells, another stem cell gave rise to two daughter stem cells.
(2) Stem cells are a small percentage of the total cellularity.
In the mouse small intestine, there are perhaps 4–5 stem cells in a ring near the bottom of the 
crypt [25] out of a total crypt population of about 250 cells. Likewise, in skeletal muscle, satellite 
cells comprise about 5% of all nuclei. In the bone marrow, the multipotential hematopoietic stem 
cell (HSC) is even more rare, with a frequency of perhaps 1 in 104-105 bone marrow cells.
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Figure 2.  Pluripotent, embryonic stem cells originate as inner mass cells within a blastocyst. The stem cells 
can become any tissue in the body, excluding a placenta. Only the morula's cells are totipotent, able to become 
all tissues and a placenta.
(3) Stem cells are undifferentiated.
In  most  tissues,  stem  cells  do  not  have  the  specialized  functions  of  the  progeny  that  they 
originate.
(4) Stem cells are slowly cycling but highly clonogenic.
In theory,  it would seem prudent to restrict stem cell division because DNA synthesis can be 
error-prone.  Thus,  in  many  tissues  we  see  that  stem  cells  divide  less  frequently  than  transit-
amplifying  cells.  In  the  intestine,  stem cells  cycle  less  frequently  than  transit-amplifying  cells, 
located more luminally [26] and in human epidermis,  integrin-bright cells  have a lower level of 
proliferation as compared to other basal cells. In hair follicles, the hair shaft and its surrounding 
sheaths are produced by the hair matrix, which is itself replenished by the bulge stem cells. The 
bulge cells divide less frequently, but are more clonogenic than the transit-amplifying cells of the 
hair matrix [27] thus showing an extensive proliferative ability.
In many tissues and organs, the identity of the stem cells has remained either elusive or at least 
equivocal [Fig.3]. However, in the bone marrow the identification of cells with the properties of 
self-renewal and multi-lineage differentiation potentialities well advanced. Indeed, such cells were 
functionally defined in the mouse back in 1961 by Till  and McCulloch [28] as cells  that,  upon 
transplantation,  were able  to  form multilineage  hematopoietic  colonies  in  the  spleen  of  lethally 
irradiated animals [colony forming units – spleen (CFU-S)].
In human bone marrow, the sialomucin CD34 is a hematopoietic cell surface antigen that has 
been  extensively  exploited  for  the  selection  of  long-term  repopulating  cells  with  multi-lineage 
potential, although not all HSCs express this. Nowadays, murine HSCs are empirically recognized 
on the basis of their immunoprofile and known as KLS cells (selected using several markers; Kit
+/Lin¯/Sca-1+).  An alternative  method for enriching HSCs exploits  the fact  that  some cells  have 
evolved a cellular protection mechanism against toxic metabolites and xenobiotics. This mechanism 
involves the activity of efflux pumps that belong to the ATP-binding cassette (ABC) superfamily of 
membrane  transporters,  and  such cells  are  able  to  efflux  a  combination  of  Hoechst  33342 and 
Rhodamine 123, thus appearing at the bottom left corner of a dual parameter FACS analysis – hence 
called  the  side  population  (SP)  [29].  SP  cells  have  been  found in  many  other  tissues,  and  the 
association between SP phenotype and stemness seems to be true in most of these tissues.
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In the central nervous system, neural stem cells and probably their transit-amplifying descendants 
express both the intermediate filament nestin and a 39 kD RNA-binding protein known as Musashi1 
[30,31]. Musashi was first identified in Drosophila and thought to be responsible for the asymmetric 
divisions of sensory organ precursor cells [32]; it may also be a marker for intestinal crypt stem 
cells.
A tissue that has been traditionally considered completely post-mitotic is the heart. However, in 
the last few years a number of studies suggested the presence of a cardiac stem cell population 
capable of (re)generating the cardiac tissue throughout life, raising the possibility to speculate about 
new  potentially  therapeutic  strategies  for  cardiac  repair.  Initial  evidence,  though  in  part 
controversial,  has been presented that  bone marrow cells  injected into damaged myocardium or 
mobilized  into  the  circulation  may  transdifferentiate  into  heart  cell  types  [33-36].  Additional, 
exciting approaches for cardiac repair have been raised by the remarkable discovery that the heart 
contains a reservoir of stem and progenitor cells. 
15
HEART
Figure 3. Adult stem cells locations
Comparing embryonic and adult  stem cells,  it’s clear that  both of them have advantages and 
disadvantages  regarding potential  use for cell-based regenerative therapies.  Of course,  adult  and 
embryonic stem cells differ in the number and type of differentiated cells types they can become. 
Embryonic stem cells can become all cell types of the body because they are pluripotent. Adult stem 
cells  are  generally  limited  to  differentiating  into  different  cell  types  of  their  tissue  of  origin. 
However, different scientific evidences suggest that adult stem cell plasticity may exist, increasing 
the number of cell types a given adult stem cell can become. A great potential advantage of using 
stem cells  from an  adult  is  that  the  patient's  own cells  could  be expanded in  culture  and then 
reintroduced into the patient. The use of the patient's own adult stem cells would mean that the cells 
would not be rejected by the immune system. This represents a significant advantage as immune 
rejection  is  a  difficult  problem that  can  only  be  circumvented  with  immunosuppressive  drugs. 
Moreover, the use of adult stem cells overcomes the ethical problem of  embryo “destruction”; that’s 
why the interest of researchers about stem cells derived from adult tissues is increasing. 
Actually,  the most stunning aspect of current progress towards cardiac regeneration is the wide 
variety of cell types that have been considered as candidates for therapeutic delivery in humans [Fig. 
4]. This myriad of cell types reflects the unmet medical need for treating heart disease, and hence 
the large amount of experimental effort being put into devising cell-based therapies. It also points to 
the lack of mechanistic understanding at many levels. The ideal cell type has not yet emerged, and 
few clinical studies are still comparing different adult stem-cell types such as skeletal myoblasts, 
endogenous  cardiac  stem  cells,  bone-marrow-derived  cells  (i.e.  haematopoietic  stem  cells, 
endothelial progenitor cells, mesenchymal stem cells etc.) but also embryonic stem cells. 
Some of these tested stem cells have been shown to improve cardiac function through various 
mechanisms,  including  the  formation  of  new  myocytes,  endothelial  cells  and  vascular  smooth 
muscle cells, as well as trough paracrine effects. 
Different  experimental  data  have shown that,  for cardiac regenerative medicine,  cardiac stem 
cells (CSCs) and bone marrow- derived mesenchymal stem cells (BMSCs) have shown the greatest 
regenerative potential.
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3.1 Cardiac stem cells
The adult heart was said for many years to be a postmitotic organ [12, 37, 38]. Of course, it was 
known that the endothelial, smooth muscle, and fibroblast cells of the heart do proliferate. But the 
cells  that  make  up  the  meat  of  the  heart—the  myocardium—were  thought  to  be  terminally 
differentiated and therefore had lost their proliferative capacity [12, 37-39]. A major implication of 
this belief is that the myocytes comprising the adult myocardium are present at birth and are not 
replenished during an individual’s life span. This traditional viewpoint was supported by several 
lines of evidence. First, studies examining mitosis in the heart showed that the number of myocytes 
undergoing  proliferation  was  either  very  low  or  nonexistent  in  the  adult  myocardium.  When 
comparing the heart to other tissues that have obvious high levels of cellular regeneration (e.g., the 
bone  marrow,  liver,  etc.),  it  was  reasonable  to  conclude  that  the  myocardium was  postmitotic. 
Second,  it  has  been  well  established  that  the  myocardium  responds  to  increased  load,  due  to 
physiological  and  pathological  stress,  principally  by cellular  hypertrophy (increase  in  cell  size) 
without obvious cellular hyperplasia (increase in cell number). Third, in response to severe injury of 
the myocardium, as occurs in an infarct,  the myocardium is unable to restore functional cardiac 
muscle within the damaged area [12, 39, 40].
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Figure 4.  Different cell types and mechanisms proposed for cardiac stem cell therapy (Figure 
from Vincent F. M. Segers and Richard T. Lee, Nature 2008)
Throughout the years,  there were several reports suggesting that cells within the myocardium 
undergo cell division [41, 42], thus challenging the prevailing concept that the adult myocardium is 
postmitotic.  However,  the  idea  that  the  adult  heart  contains  at  least  some  newly  regenerated 
myocytes has only been taken seriously during the past five years [43-45]. In 2003, in fact, several 
independent groups reported the discovery of resident progenitor cells in heart tissue, which would 
have the capacity to regenerate sections of the healthy or injured myocardium [46-48]. 
In one such study, a Lin- c-Kit+ cell was isolated from the adult rat heart, and it was reported to be 
self-renewing,  clonogenic,  and  multipotent,  being  able  to  give  rise  to  cardiomyocytes,  smooth 
muscle  cells,  and  endothelial  cells  [49].  The  cells  were  injected  into  ischemic  hearts  and  were 
reported  to  reconstitute  up  to  70%  of  the  myocardium,  forming  both  new  vessels  and 
cardiomyocytes. More importantly, the authors reported a significant increase in cardiac function of 
the animals that had received these cells. In a similar study, the same cell type was delivered to the 
coronary arteries of rats that had had a myocardial infarct, via a catheter positioned into the aortic 
root [50]. The cells were reported to induce myocardial regeneration through the decrease of the 
infarct size by 29% and also to improve the function of the injured heart. 
At about the same time, a different type of adult cardiac stem cell was reported by Oh et al [51]. 
The  cells,  isolated  from  adult  mouse  hearts,  were  Sca-1+ and  initiated  in  vitro  cardiac  gene 
expression after  treatment  with the DNA demethylating agent 5-azacytidine.  A mouse model  of 
ischemia/ reperfusion injury was used to assay the in vivo capacity of the Sca-1+ cardiac stem cells 
to regenerate the infarcted myocardium. Transplanted cells initiated production of cardiac functional 
proteins and were identified in the mouse hearts 2 weeks after injection. Fusion between the donor 
cells and the host cardiomyocytes was evident in about 50% of the identified cells, whereas the other 
50% had differentiated into cardiomyocytes. 
Martin et al [52] reported on the identification of a resident cardiac population of adult stem cells 
with the unique expression of the  Abcg2 transporter  protein  (Side  Population  Cells-SPCs).  The 
Abcg2+ cells were reported to differentiate into alpha actinin-positive cells when cocultured with 
adult  cardiomyocytes;  however, when cultured individually in methylcellulose,  they gave rise to 
hematopoietic colonies. Finally, gene expression analysis revealed a unique transcriptional signature 
similar to that of endothelial and hematopoietic progenitor cells. Cell-based cardiac therapies using 
the Abcg2+ cells are underway.
Islet-1, a LIM homeodomain transcription factor, is uniquely expressed in the adult heart by the 
fourth identified cardiac stem cell population. This marker is expressed by cardiac progenitor cells 
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in the secondary cardiac field, a structure present during early development, which contributes to 
most cells in the heart [53]. During development, proliferating progenitor cells in the outflow tract, 
the right ventricle, and the atrium express isl1, without which they cannot contribute to the heart. 
Isl1+ cells were identified in the postnatal rat, mouse, and human myocardium [54].
A  technique  of  conditional  genetic  marking  was  used  to  identify  the  isl1+ population  in  a 
temporal/spatial manner. This allowed the authors to selectively isolate the isl1+ cells at a particular 
developmental  stage.  When  cocultured  with  isolated  cardiac  mesenchymal  cells,  the  isl1+ cells 
maintained  isl1  expression and proliferated  in  culture  without  differentiating.  The  isolated  cells 
could be induced to differentiate in culture into cardiomyocytes after exposure to 4-OH-TM or after 
coculture with neonatal cardiac myocytes. No cell-based cardiac therapy experiments have yet to be 
reported involving the isl1+ cardiac stem cells.
The four adult cardiac stem cell populations reported isolated are Lin-/c-Kit+, Sca-1+, Abcg2+, and 
isl1+ cells. When these cell types were examined for markers expressed by the rest of the stem cell 
populations, it was found that the c- Kit+ cells did not express Sca-1, the Sca-1+ cells did not express 
c-Kit,  and the isl1+ cells  did not  express c-Kit  or Sca-1.  The Abcg2+ cells  were reported to be 
approximately 50% Sca-1+ and only about 2% c-Kit+ (no data were given for isl1).
Therefore,  cardiac  stem  and  progenitor  cell  types  characterized  so  far  exhibit  significant 
differences in their  immunophenotypic,  developmental  and biological properties. Thus, the heart 
probably contains various types of stem and progenitor cells. This is in agreement with the emerging 
consensus that more than one stem cell may be present in a particular tissue [55], and with recent 
evidence  that  heart  endothelial,  cardiac  and  muscle  cells  may  arise  from  a  hierarchy  of 
multipotent/bipotent stem progenitor cells [56-58, Fig.5]. The developmental origin(s) of stem and 
progenitor  cells  of  the adult  heart  has  been studied only to  a  very limited  extent  [59].   Mouse 
chimera experiments suggest that most (at least 95%) cardiomyocytes are derived from a relatively 
small embryonic founder population, ruling out any major contribution to the adult cardiomyocyte 
population from “immigrant” non-cardiac stem cells, at least under physiological conditions [60]. 
On  the  other  hand,  several  findings,  including  the  presence  of  cardiac  chimerism  in  patients 
receiving  allogeneic  bone  marrow transplantation,  suggest  that  immigrant  bone  marrow-derived 
cells could behave, under pathological conditions leading to heart damage, as precursors of cardiac 
stem cells  [61].  Thus,  the  important  issue  of  extra-cardiac  sources  of  CSCs,  following  cardiac 
damage, still needs to be addressed. If extra-cardiac cells can be induced, not only to migrate to the 
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heart,  but  also  to  reconstitute  a  pool  of  extensively  replicating  CSCs,  exciting  therapeutic 
possibilities may arise. 
Moreover,  if  these  Lin-/c-Kit+,  Sca-1+,  Abcg2+,  and  isl1+ described  progenitor/stem  cell 
populations  reside  in  the  myocardium,  it  would  be  informative  to  examine  why  under  normal 
circumstances they do not regenerate the myocardium and how can we stimulate them to do so.
3.2 Bone marrow mesenchymal Stem Cells
About 40 years ago Friedenstein described stromal cells in the bone marrow that were spindle 
shaped and proliferate to form colonies [62]. These cells attach to plastic and are able to differentiate 
under  defined  in  vitro conditions  into multiple  cell  types  present in many different  tissues,  e.g. 
osteoblasts, chondroblasts, adipocytes and, more recently, cardiomyocytes and vascular endothelial 
cells  [21,  63,  Fig.6].  Later  on  these  cells,  obtained  from  postnatal  bone  marrow,  were  called 
mesenchymal stem cells (MSCs) or stromal stem cells [64, 65]. The term mesenchymal stem cells 
(MSC) was  popularized  by  Caplan  [66],  in  reference  to  work  by Friedenstein  and  Owen [67], 
describing  a  plastic-adherent  fibroblastic  cell  isolated  by Percoll  density  centrifugation,  reactive 
with  monoclonal  antibodies  SH2 and SH3.  The  adjective  ‘mesenchymal’  is  fraught  with  some 
ambiguity since ‘mesenchyme’  describes tissue of mesodermal  origin,  the middle embryological 
germ layer,  giving rise to the musculoskeletal,  blood, vascular and urinogenital  systems,  and to 
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Figure 5.   Stem and progenitor cells are present in heart tissue.
connective  tissue  (including  dermis).  Thus,  developmentally  speaking,  the  term  ‘mesenchymal’ 
should include both blood and connective tissue cells. In practice however, only the latter cells are 
usually described as being derived from MSC and considered distinct from haematopoietic stem 
cells (HSC), which are responsible for the development, maintenance, and regeneration of blood 
forming tissues [68]. It is quite possible that MSC and HSC have a common precursor in the elusive 
‘‘haemangioblasts’’  [69],  in  the  cells  identified  by  the  group  of  Verfaillie  originally  termed 
‘‘mesodermal  progenitor’’  [70],  later  ‘‘multipotent  adult  progenitor’’  (MAPC)  [71]  cells,  or  in 
‘‘pluripotent  stem cells”  [72]  ,  or  ‘tissue committed  stem cells’  (TCSC) [73].  However,  this  is 
contentious and the physiological relevance of these cells remains to be demonstrated.
Recently the presence of somewhat similar cells has been demonstrated in many other tissues too. 
In fact, different studies have shown that  MSCs reside not only in bone marrow but also in other 
tissues such as adipose tissue [74] , synovium [75] , periosteum [76] , muscle [77] , dental pulp [78], 
periodontal ligament [79] , placenta [80] and umbilical cord blood [81]. A recent study suggests that 
MSC reside in virtually all postnatal organs and tissues, and may be localized to vessel walls [82]. 
Bone marrow-derived MSC, which are most investigated, are a rare subpopulation of bone marrow 
cells (approximately 0.001-0.01%) [21].
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Figure 6.  Bone marrow stem stell are multipotent stem cells.
So  far  the  nomenclature  is  not  consistent.  Designations  for  cells  with  nonhaematopoietic 
multipotency  have  included  ‘‘colony-forming-unit-fibroblasts’’,  ‘‘stromal  (stem)  cells’’,  ‘‘bone 
marrow  (stromal)  cells’’,  ‘‘skeletal  stem  cells’’,  ‘‘mesodermal  progenitor  cells’’,  ‘‘non-
haematopoietic  stem cells’’,  ‘‘(bone marrow) stem cells’’,  ‘‘mesenchymal  progenitor  cells’’  and 
others [71, 83]. There is also an understandable tendency to designate such cells as ‘‘pre-(lineage-
under-investigation)’’ cells (e.g. pre-osteoblast etc.). It has also been suggested that MSC are simply 
pericytes [84]. Some of the inconsistencies surrounding the identification of MSC arise from the fact 
that specific markers have not yet been agreed on. In the absence of a universal antigenic indication 
(analogous to CD34+ for HSC) and an universal assay (analogous to the repopulation assays for 
HSC) MSC are often identified simply by testing a cultures’ differentiation potential into colony 
forming units (CFU) indicative of proliferative capacity and into several lineages of mesenchymal 
tissue as defined above [21]. Also, the ability to adhere to tissue culture plastic and a fibroblastlike 
morphology are taken as characteristic markers for MSC [66]. Recently, different surface markers 
have been associated with MSC including D7fib [85], Stro1 [86], CD45 and glycophorin A [21, 70, 
87], BMPR1a [83, 88].
Further complications arise when different sources, extraction and cultivation methods are used. 
Even when narrowing sources to bone marrow, the site of extraction is reported to influence cell 
behaviour: e.g. MSC from alveolar bone show less chondrogenic and adipogenic potential compared 
to iliac bone [89] . Isolation is usually conducted by density centrifugation (sometimes enhanced by 
gradient  solutions) to obtain the mononuclear  fraction of marrow cells  and by using the widely 
reported ability of MSC to adhere to tissue culture plastic [90]. Newer methods employ magnetic 
beads  [86] or  FACS sorting [91]  in  conjunction  with antibodies  to  the proposed MSC markers 
above.  Additionally,  widely differing standards regarding serum composition,  culture  conditions, 
and growth factor application in MSC cultivation exist. Differing conditions can lead to enrichment 
of different subsets of MSC with differing clonogenic potential. All these potential deviation points 
in current methods are summarised in Table 1.
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Table 1  
Extraction sites (Prinz et al., 1999)
Bone marrow (live donors—partial samples only): hip, sternum, broken bones (rare)
Bone marrow (cadaver donors): all sites (rare)
Other tissue: teeth, fat, muscle, cartilage, synovial fluid, skin
Developmental tissue: foetal, umbilical, placenta
Dissociation method
Trypsination
Scraping
Suspension culture
Marker combinations
CD10+, CD13+, CD34+, CD56+, CD90+, MHC-1+ (Young et al., 1999)
CD10_, CD13+, CD31_, CD34_, CD44+, CD45_, CD90+, CD105+, CD133_
Wnt2+ ,Wnt4+, Wnt5a+, Wnt11+, Wnt16+, Fz2+, Fz3+, Fz4+, Fz5+, Fz6+ (Etheridge et al., 2004)
VCAM+, STRO-1+, CD73+, CD105+ (Tuli et al., 2003)
GlyA_, CD45_ (Reyes et al., 2001)
D7-FIB+, CD13+; CD45_, GPA_, LNGFR+ (Jones et al., 2002)
SH2+; SH3+; CD14_; CD29+, CD34_, CD44+; CD45_, CD71+, CD90+, CD106+, CD120a+,
CD124+ (Pittenger et al., 1999)
Identification
Adherence to plastic
Magnetic bead
FACS cell sorting
Other factors
Cell line or ex vivo
Donor age
Donor sex
Donor disease status
Point of first analysis
Seeding density
Feeder cells used
Culture conditions (temperature, motion, etc.)
Differentiation agent
Medium composition
First medium change
Frequency of medium change
Listed are some variables in MSC description where differing standards reportedly or likely result in influencing 
cell behaviour or otherwise lead to variant data
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Since MSC can be rather easily isolated from the bone marrow and can also be expanded in vitro 
they have become a prime target for researchers of tissue regeneration. These cells have now been 
extensively used for transplantation experiments in animals and also for some therapeutic trials in 
humans. However, much new research is needed to learn enough on the molecular mechanisms of 
MSC differentiation to evaluate their full capacity for tissue regeneration. Mesenchymal stem cells 
have been studied in great detail and scientists have advanced knowledge about how to grow these 
cells in culture. Unlike most other human adult stem cells, mesenchymal stem cells can be obtained 
in quantities appropriate for clinical applications, making them good candidates for use in tissue 
repair. Techniques for isolation and amplification of mesenchymal stem cells in culture have been 
established and the cells  can be maintained and propagated in culture for long periods of time, 
without loosing their capacity to form all the above cell types.
3.2.1 Bone Marrow-MSC and cardiac repairing
In vitro studies have demonstrated that bone marrow stem cells (BMSC) can differentiate not 
only into adipocytes and osteocytes, but also into cardiomyocytes and vascular endothelial cells in  
vivo and  in vitro [21, 63, 92-94]. Conversely, it has also been reported that the differentiation of 
BMSC into cardiomyocytes occurs rarely, if at all [95-97]. There is no consensus on the plasticity of 
BMSC,  including  their  differentiation  into  functional  cardiomyocytes;  however,  experimental 
studies and clinical trials have demonstrated that the implantation of bone marrow-derived cells can 
improve regional perfusion and cardiac function of the injured heart, by rebuilding the damaged 
myocardium and cardiac vessels [98-100]. Thus, autologous BMSC are still one of the most studied 
cell sources for myocardial repair. 
Different  researchers  tested  the  in  vitro  capacity  of  mouse  bone  marrow–derived  MSCs  to 
differentiate  into  cardiomyocytes  in  cultures  containing  either  BMSC  alone,  treated  with  5-
azacytidine or a cocktail of growth factors and in co-culture with cardiomyocytes [101, 102]. The in 
vitro differentiation of BMSC into cardiomyocytes was first reported in 1999 by Makino et al. [92]. 
The authors induced the cells to differentiate by treating them with 5-azacytidine: a global DNA 
demethylating agent that acts as a cytosine analog capable of altering expression of certain genes 
that may regulate differentiation. The morphology of about 30% of the treated cells changed within 
a  week  of  treatment,  and  by  the  second  week,  the  cells  were  spontaneously  contracting  and 
expressing  cardiac  specific  proteins.  Bittira  et  al  [103] also  reported  the  isolation  of  rat  bone 
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marrow–derived MSCs. LacZ labeled cells received either 5-azacytidine treatment or no treatment 
and  were  subsequently  injected  into  the  cryoinjured  myocardium of  isogenic  rats.  The  authors 
reported that 4 to 8 weeks postinjection, the treated cells appeared myotube-like while expressing 
the cardiac marker troponin I-C. The data from both studies suggest that cell treatment with a DNA 
demethylating agent is necessary for the differentiation of MSCs into cardiomyocytes.
The effect of bone marrow–derived MSCs on cardiac function after myocardial infarction was 
also examined. A study reported by Shake  et al [104] focused on the implantation of autologous 
MSCs  in  a  swine  myocardial  infarct  model.  Labelled  cells  were  administered  2  weeks 
postmyocardial  infarction  in  the  infarcted  area  through direct  injection.  The  authors  reported  a 
significant  attenuation  in  the degree  of  contractile  dysfunction  in  the  transplanted  animals  with 
reduced wall thinning in the infarcted region of the myocardium. In the second study, bone marrow 
MSCs were injected into the tail vein of rats that had had a myocardial  infarct (MI) [105]. The 
MSCs were reported to be recruited to the injured heart through the expression of the stromal cell-
derived factor-1 (SDF-1), enhance angiogenesis, and improve cardiac function. The same authors 
also reported in another study that lacZ labelled rat bone marrow–derived MSCs were injected into 
the tail vein. The cells were able to home to the injured area of the heart and were found at high 
concentrations in the peri-infarct region of the myocardium [106]. 
Toma et al [107] reported the injection of lacZ labelled human bone marrow– derived MSCs into 
the left ventricle of mice.  One week postinjection,  only a limited number of cells had survived; 
however,  these  cells  were  reported  to  express  cardiac-specific  markers  similarly  to  the  host 
myocardium.  Hattan  et  al [108]  used  a  transgene  that  allowed  expression  of  GFP  under  a 
ventricular-specific promoter. After MSC differentiation, GFP+ cells were sorted and transplanted 
into the adult mouse myocardium with a reported long-term survival. In a most recent report, MSCs 
cultured in the presence of cardiogenic growth factors were injected into the myocardium of dogs 
that had had a myocardial  infarct  (coronary artery ligation) 8 weeks prior to the injections. The 
authors report significant functional recovery of the transplanted hearts [109]. Bone marrow–derived 
MSCs are reported to have the ability to home to the areas of the heart that have sustained an injury 
as a result of a myocardial infarct. They have also been shown to express cardiac markers in the 
myocardium independent of 5-azacytidine treatment.  One of their  advantages is that  they are an 
autologous cell source obviating the need for immunosuppression therapy [110]. 
However, the time needed for MSCs to proliferate in culture to a sufficient cell number needed 
for the transplantation is far longer than the short amount of time the patient has postinfarction for 
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the injection of these cells as shown by Bittira et al [103].  The capacity of these cells to completely 
regenerate the infarcted myocardium has not been proven yet; so far it’s clear that the presence of 
the cells in the myocardium decreases the potential infarct size but the mechanism is still unclear 
and poorly understood.
More recently, it has been shown that MSC should exert their effect on cardiac regeneration not 
only by differentiation into specific cell types, but also through paracrine actions. In vitro studies 
have  demonstrated  that  MSC  can  secrete  a  variety  of  angiogenic,  antiapoptotic  and  mitogenic 
factors  such  as  vascular  endothelial  growth  factor  (VEGF),  hepatocyte  growth  factor  (HGF), 
adrenomedullin  (AM)  and  insulin-like  growth  factor-1  (IGF-1)  [111,  112].  Interestingly, 
administration of conditioned medium obtained from MSC culture exerted cytoprotective effects on 
the  myocardium  in  an  animal  model  of  myocardial  infarction  [113].  Ohnishi  et  al [114] 
demonstrated that cultured cardiomyocytes were injured in response to monocyte chemoattractant 
protein-1  (MCP-1),  which  plays  an  important  role  in  myocarditis,  whereas  this  effect  was 
significantly attenuated by conditioned medium derived from MSC culture. These results suggest a 
cardioprotective  effect  of  MSC acting  in  a  paracrine  manner,  demonstrating  the  importance  of 
secreted factors in cardiac repair.
4. Cell delivery in cardiac stem cell therapy
Functional benefits of cell therapy for cardiovascular applications may arise from induction of 
angiogenesis, cardiomyogenesis or mechanical interstitial support. The former two modes of benefit 
may result from site-specific transdifferentiation of administered cells or by secretion of paracrine 
factors that may stimulate endogenous repair mechanisms. On this basis, improvements in regional 
myocardial  perfusion,  systolic  function,  diastolic  function  and  adverse  ventricular  remodelling 
would be predicted. The additional mechanical interstitial support provided by cell administration 
may  itself  impact  beneficially  on  the  ventricular  remodelling  process.  Clearly  these  potential 
benefits need to be weighed against the potential toxicity from cell therapy, such as exacerbation of 
atherosclerosis, arrhythmogenesis, inappropriate calcification and local or ectopic tumor formation. 
The  optimal  cell  preparation  for  each  of  the  variety  of  potential  cardiovascular  applications 
remains to be determined. It cannot be assumed that one cell preparation will be equally efficacious 
for  all  clinical  applications,  and different  cell  preparations  may have  varying  toxicity  profiles  . 
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Indeed,  it  is  unclear  if  administration  of  a  highly  selected  cell  population  is  preferable  to  a 
heterogeneous unselected or combination cell product [115]. 
Other unresolved issues include determination of the optimal number of cells to be delivered, 
timing of cell administration, importance of growth factor preconditioning of cellular products prior 
to administration, how to follow transplanted cells once they are in the body, effects of ex vivo cell 
expansion and prolonged cell culture prior to administration, and the use of allogeneic rather than 
autologous cell populations [Table 2].
Table 2
Comparison of allogeneic and autologous cell preparations (from R de Silva and RJ Lederman, 2004)
      About  the sources of cell  for cardiac  transplant,  cardiac and bone marrow stem cells  are 
described by different researchers as the cells with the best potentiality in cardiac regeneration. Very 
little data is available to guide cell dosing. Scientific data suggests that there is a dose-dependent 
improvement in function but it is still unclear which is the best dose to warranty a real functional 
cardiac improvement. 
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Determining  optimal  delivery  methods  raise  issues  not  only  of  dose,  but  also  of  timing. 
Moreover, assessing the fate of injected cells is critical to understanding mechanisms of action. 
For therapeutic purposes, cells should be delivered to the target tissue of interest in sufficient 
number to confer functional benefit with minimal toxicity to the recipient.
For cardiovascular applications, modes of cell delivery may be broadly categorized as systemic 
or  local  [Table  3].  Systemic  delivery  may  consist  of  intravenous  infusion  of  cells  or  cytokine 
mobilization of cells into the circulation. The homing of systemically administered cells to the target 
tissue of interest requires appropriate chemokine signalling from the target tissue. The intensity of 
these homing signals appears to decline with time following an acute injury and may determine the 
time window during which systemic cell administration may confer functional benefit. Studies in 
rodents  have  demonstrated  the  ability  of  human  progenitor  cells  from  G-CSF-mobilized 
leukapheresis products [99] and rat allogeneic mesenchymal stromal cells [116] to home to regions 
of  acute  myocardial  infarction  following  intravenous  administration.  In  the  former  study, 
improvements in ejection fraction and attenuation of adverse cardiac remodelling were noted on the 
basis of echocardiography. Other animal studies have demonstrated that cytokine mobilization may 
confer hemodynamic benefits in a murine model of acute coronary artery ligation [117]. However, 
scientific and clinical data suggest that systemic cell delivery may not be optimal in the setting of 
acute or chronic coronary syndromes, although further studies are required.
Table 3
Route of cell delivery (from R de Silva and RJ Lederman, 2004)
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Local delivery is theoretically more attractive than systemic in that larger numbers of cells may 
potentially be administered to specific regions of interest within the target organ. Local delivery 
systems should be biocompatible with the cell preparation to be administered,  such that there is 
minimal loss of cell number and cell viability as a consequence of passage through the delivery 
system. Clinically, local cell delivery can be achieved by direct injection at the time of open heart 
surgery or by percutaneous catheter-guided intracoronary infusion or intramyocardial injection.
For example, surgical delivery is excellent for performing intramyocardial cell injection targeted 
to infarct borders. Using this method the cells are directly transplanted close to the damaged area in 
order  to  facilitate  cell  grafting  and the  regenerative  process.  Others  local  delivery methods  are 
represented by catheter delivery. Percutaneous catheter-based approaches are available for delivery 
of cells to the myocardium via intracoronary infusion, endomyocardial injection, transcoronary vein 
intramyocardial  injection,  transcoronary  sinus  retrograde  infusion  and  intrapericardial  injection. 
Intracoronary infusions can be performed down the infarct-related artery [100] and endomyocardial 
injections  can  be  localized  to  peri-infarct  regions  using  an  electromechanical  mapping  system 
[118,119]. Targeted cell delivery may also be achieved using real-time magnetic resonance imaging 
(MRI) [120, 121] techniques and cells labelled with particles [122], which appear as signal voids on 
the  magnetic  resonance  (MR)  image.  Using  this  sophisticated  technology,  cell  delivery  can  be 
targeted in real time precisely to infarct borders. 
Anyway, there are several major unresolved issues in cell delivery. The optimal delivery route 
has  not  been  established.  There  are  few  quantitative  data  addressing  cell  distribution  and  cell 
retention as a function of the mode of cell delivery. Biodistribution studies using technetium-99m 
labeled BM-derived mesenchymal  stromal cells  in recently infarcted rats suggest that,  following 
intravenous  infusion,  the  vast  majority  of  infused  cells  are  entrapped  in  the  lungs  with  little 
distribution to the heart [123]. The number of cells in the heart was increased by infusion of cells 
directly into the left ventricular cavity [123]. Retention of cells following direct  intramyocardial 
injection was not assessed in this study. Other pre-clinical data suggest that at best only 30–40% of 
particulate  material  is  retained  within  the  myocardium  following  a  successful  endomyocardial 
injection  [124].  Clearly,  significant  improvements  in  cell  retention  and  its  quantification  are 
required.  Furthermore,  the  biocompatibility  of  interventional  devices  with  therapeutic  cell 
preparations needs further assessment. Variability in cell number, viability, migratory, proliferative 
and differentiation capacity as a function of cell handling and interaction with the delivery system 
may be important determinants of the efficacy of cardiac stem cell therapy.
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5. Tissue-engineering: a new approach for cell delivery in cardiac regenerative medicine
The poor survival of grafted cells has been a concern of researchers. Given the poor vascular 
supply after a heart attack and an active inflammatory process, grafted cells survive with difficulty. 
As mentioned above, the efficacy of cell engraftment by injection of a cell suspension is generally 
very low as more than 90% of the cells injected is lost and does not engraft [125].  It is necessary to 
provide cells an environment that is suitable to proliferation and differentiation for the induction of 
tissue regeneration.
Thus, much effort is now conveyed to the development of alternative cell delivery system. One of 
these new strategies is the  tissue-engineering strategy,  in which biomatrices are used to generate 
three-dimensional cell constructs able to provide a physiological support to the cells, allowing to 
successfully engrafting new cells into the myocardium.
Tissue-engineering combines cells, engineering and materials methods, and suitable biochemical 
and physio-chemical factors to improve or replace biological functions. While most definitions of 
tissue engineering cover a broad range of applications, in practice the term is closely associated with 
applications that repair or replace portions of or whole tissues (i.e., bone, cartilage, blood vessels, 
heart etc...). 
Often,  the  tissues  involved  require  certain  mechanical  and  structural  properties  for  proper 
function. The term has also been applied to efforts to perform specific biochemical functions using 
cells within an artificially-created support system.
A commonly applied definition of tissue engineering, as stated by Langer and Vacanti, is "an 
interdisciplinary  field  that  applies  the  principles  of  engineering  and  life  sciences  toward  the 
development of biological substitutes that restore, maintain, or improve tissue function or a whole 
organ" [126].  Tissue engineering has also been defined as "understanding the principles of tissue 
growth, and applying this to produce functional replacement tissue for clinical use” [127]. 
Scientific  advances  in  biomaterials,  stem  cells,  growth  and  differentiation  factors,  and 
biomimetic environments have created unique opportunities to fabricate tissues in the laboratory 
from combinations of engineered extracellular matrices ("scaffolds"), cells, and biologically active 
molecules.  Tissue-engineering utilizes  living cells  as engineering materials,  the scaffold for cell 
proliferation and differentiation, and, eventually, growth factors which has the potential to accelerate 
tissue regeneration. 
The utilized cells are often categorized by their source in:
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• Autologous cells are obtained from the same individual to which they will be reimplanted. 
Autologous  cells  have  the  fewest  problems  with  rejection  and  pathogen  transmission, 
however in some cases might not be available. Moreover since this category of cells needs to 
be harvested from the patient, there are also some concerns related to the necessity of per-
forming such surgical  operations  that might  lead to donor site infection or chronic pain. 
Autologous cells  also must be cultured from samples before they can be used: this takes 
time, so autologous solutions may not be very quick. Recently there has been a trend towards 
the use of mesenchymal stem cells from bone marrow and fat. A large number of cells can 
be easily and quickly isolated from fat and bone marrow.
• Allogenic  cells  come from the body of a donor of the same species. While there are some 
ethical constraints to the use of human cells for in vitro studies, the employment of dermal 
fibroblasts from human foreskin has been demonstrated to be immunologically safe and thus 
a viable choice for tissue engineering of skin.
• Xenogenic cells are those isolated from individuals of another species. In particular animal 
cells  have  been  used  quite  extensively  in  experiments  aimed  at  the  construction  of 
cardiovascular implants.
• Syngeneic’ or isogenic cells are isolated from genetically identical organisms, such as twins, 
clones, or highly inbred research animal models. 
• Stem cells  are undifferentiated cells with the ability to divide in culture and give rise to 
different forms of specialized cells.  According to their source stem cells are divided into 
"adult" and "embryonic" stem cells, the first class being multipotent and the latter mostly 
pluripotent some cells are totipotent, in the earliest stages of the embryo. While there is still 
a large ethical debate related with the use of embryonic stem cells, it is thought that stem 
cells may be useful for the repair of diseased or damaged tissues, or may be used to grow 
new organs.
Cells  are  often  implanted  or  'seeded'  into  an artificial  structure  capable  of  supporting  three-
dimensional tissue formation. These structures, typically called scaffolds, are often critical, both ex 
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vivo as well as in vivo, to recapitulating the in vivo milieu and allowing cells to influence their own 
microenvironments. Scaffolds usually serve at least one of the following purposes:
• Allow cell attachment and migration 
• Deliver and retain cells and biochemical factors 
• Enable diffusion of vital cell nutrients and expressed products 
• Exert certain mechanical and biological influences to modify the behavior of the cell phase
• Protect trasplanted cells from the immunological attack.
 
It is necessary for tissue regeneration to increase the number of cells constituting the tissue as 
well  as  reconstruct  a  structure  of  extracellular  matrix  (ECM)  to  support  the  proliferation  and 
differentiation of cells for regeneration induction. In addition, it is necessary to allow cells of high 
potential to proliferate as well as to maintain their biological function.
To achieve the goal of tissue reconstruction, scaffolds must meet some specific requirements. The 
materials should be well deliquesced with contiguous tissues after transplantation without or with a 
very  low  inflammatory  reaction.  They  must  have a  high  porosity  and  an  adequate  pore  size, 
necessary to facilitate cell seeding and diffusion throughout the whole structure of both cells and 
nutrients. Biodegradability is often an essential factor since scaffolds should preferably be absorbed 
by the surrounding tissues without the necessity of a surgical removal. The rate at which degradation 
occurs has to coincide as much as possible with the rate of tissue formation: this means that while 
cells are fabricating their own natural matrix structure around themselves, the scaffold is able to 
provide structural integrity within the body and eventually it will break down leaving the neotissue, 
newly formed tissue which will take over the mechanical load.
Many  different  materials  (natural  and  synthetic,  biodegradable  and  permanent)  have  been 
investigated. Most of these materials have been known in the medical field before the advent of 
tissue-engineering as a research topic, being already employed as bioresorbable sutures. Examples 
of these materials are collagen or some linear aliphatic polyester.
New biomaterials have been engineered to have ideal properties and functional customization: 
synthetic manufacture, biocompatibility, non-immunogenicity, transparency, nano-scale fibers, low 
concentration, resorption rates, etc.
A commonly used synthetic material is polylactic acid (PLA). This is a polyester which degrades 
within the human body to form lactic acid, a naturally occurring chemical which is easily removed 
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from the body. Similar materials are polyglycolic  acid (PGA) and polycaprolactone (PCL): their 
degradation mechanism is similar to that of PLA, but they exhibit respectively a faster and a slower 
rate of degradation compared to PLA. Scaffolds may also be constructed from natural materials: in 
particular different derivatives of the extracellular matrix have been studied to evaluate their ability 
to support cell growth. Proteic materials, such as collagen or fibrin, and polysaccharidic materials, 
like chitosan or glycosaminoglycans (GAGs), have all proved suitable in terms of cell compatibility, 
but  some  issues  with  potential  immunogenicity  still  remains.  Among  GAGs  hyaluronic  acid, 
possibly in combination with cross linking agents (e.g. glutaraldehyde, water soluble carbodiimide, 
etc...), is one of the possible choices as scaffold material. Functionalized groups of scaffolds may be 
useful in the delivery of small molecules (drugs) to specific tissues.
5.1 Materials as scaffolds for cells transplantation in cardiac tissue-engineering
One of the first materials used for tissue-engineering of the heart was based on hydrolytically 
degradable  biocompatible polymers  composed of polyactic  acid (PLA), polyglycolic  acid (PGA) 
and their copolymer polylactic-co-glycolic acid (PLGA) [128]. Subsequently, researchers realized 
that the mechanical properties of the material used had to be adapted to the elastic properties of the 
heart tissue. Therefore, most research is focusing on the use of scaffold made of different synthetic 
and/or natural polymers. Table 4 gives an overview on different materials used in the past few years 
for the regeneration of the heart [125]. It has to be pointed out that only a few materials were tested 
in humans, while many animal studies were carried out in rats and dogs.
                                    Table 4
                                    Materials used in the past three years for cardiac tissue engineering
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Several groups are currently working with scaffold materials composed of natural polymers such 
as  collagen  [125,  129,  130],  this  latter  being  the  major  constituent  of  the  cardiac  extracellular 
matrice  (ECM).  Promising  results  in  the  development  of  collagen-based  grafts  or  ‘patches’ 
containing  beating  cardiomyocytes  were  obtained  in  Canada  [129]  and  Germany  [130].  These 
studies  comprised  the  application  of  cardiomyocyte-seeded collagen  strings  that  were cyclically 
stretched, thus providing patches with improved morphology and contractile function. Zimmermann 
et al [125] demonstrated that these collagen patches could survive and beat for up to eight weeks 
after engraftment on the heart of immunosuppressed rats. 
Similar approaches and results were obtained using alginate-based scaffolds by Cohen et al. in 
Israel  [131,  132].  Alginate,  a  negatively  charged  polysaccharide  from  seaweed  which  forms 
hydrogels in the presence of calcium, offers the advantage of detecting ECM formation by cardiac 
cells to follow not only the proliferation and migration of the cells, but also the kinetics of ECM 
formation. After implantation into the infarcted rat myocardium, the alginate-biografts were shown 
to  stimulate  intense  neovascularization  and  to  attenuate  left  ventricular  dilatation  and  failure, 
compared with control rat hearts [132]. 
Composites of natural and synthetic polymers were also developed; for example, sponges based 
on caprolactone-co-L-lactide reinforced with knitted poly-L-lactide fabric (PCLA), gelatin or PGA. 
Using rat aortic smooth muscle cells, an increased colonization of the right ventricular outflow tract 
was obtained using gelatin or PCLA, but not with PGA-reinforced grafts [133]. Another interesting 
synthetic material is based on 1,3-trimethylene carbonate and D,L-lactide copolymers [134, 135], 
which have the ability to be reabsorbed over a ten month period and to sustain the cyclic loading of 
the  heart  muscle  under  physiological  conditions.  However,  as  yet  no animal  studies  have  been 
carried out with this amorphous material. The most fascinating approach to the regeneration of heart 
has  been  proposed by Shimizu  and co-workers  [136],  who used  materials  to  create  electrically 
communicating three-dimensional  cardiac tissue layers [Fig.  7, panel c].  In this  case,  cells  were 
adhered on tissue-culture plates previously coated with poly(N-isopropylacrylamide) (PIPAAm), a 
temperature-sensitive polymer. At 37°C PIPAAm is hydrophobic, enabling cell adhesion and access 
to  the binding sites  offered on this  modified  surface;  at  a lower temperature such as 32°C, the 
surface becomes hydrophilic  and inappropriate  for cell  adhesion due to the rapid hydration and 
swelling  of  PIPAAm.  Using  poly(vinylidene  difluoride)  (PVDF)  membranes,  which  are 
hydrophobic, the detaching cell layers can be collected and handled, providing up to four conducting 
layers of synchronously beating cardiomyocytes. When these patches were implanted on rats with 
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induced myocardial  infarction,  an improved  myocardial  contractility  was  observed,  concomitant 
with the appearance of a vascular network within a few days after  implantation [137]. Figure 7 
summarizes three of the major approaches to cardiac engineering described above, based on the use 
of collagen, hydrogel or multiple layers.
More recently researchers are using another natural component of ECM as support for cardiac 
stem cell transplantation: hyaluronic acid (HA). HA is a naturally occurring polysaccharide, and is 
one  of  the  basic  components  of  the  ECM  of  connective  tissue.  HA  is  biocompatible  and 
biodegradable  and  exhibits  an  unusual  and  distinctive  set  of  physicochemical  and  biological 
properties, enabling it to regulate and control several physiological functions of tissue [138]. It plays 
a major role in tissue growth and remodelling, interacting specifically with endogenous receptors 
such  as  CD44  and  intracellular  adhesion  molecule-1  (ICAM-1)  to  guide  and  control  cellular 
migration, growth and adhesion [139]. It also regulates macromolecular traffic within the interstitial 
space in joints contributing to lubrication and to the strength in compression of soft tissue [140]. 
Twenty  years  after  the  initial  discovery  of  HA,  Meyer’s  laboratory  determined  the  exact 
chemical structure of HA, a non sulfated, highmolecular-weight glycosaminoglycan composed of 
35
Figure 7.  Scheme of the present major strategies of cardiac tissue engineering using (a) collagen strings, (b) biodegradable gels or (c) 
cardiac  cell  sheets.  The  incorporation  of  growth  factors  and/or  cytokines  (triangles)  may  have  a  crucial  role  to  support  cell 
differentiation, engraftment and survival, both within the scaffolds and in vivo, thus improving the overall cardiac function. (Figure 
from (Zammaretti and Jaconi, 2004)
repeating  polymeric  disaccharides  d-glucuronic  acid  and  N-acetyl-dglucosamine  linked  by  a 
glucuronidic  β(1→3)  bond  [141].  The  disaccharide  units  are  then  linearly  polymerized  by 
hexosaminidic  β(1→4) linkages (Fig.8). Hyaluronan can be 25,000 disaccharide repeats in length 
and  reach  a  molecular  weight  of  4000 kDa.  HA is  synthesized  by  membrane-bound  synthases 
(HASs) at the inner surface of the plasma membrane, and the chains are extruded through pore-like 
structures into the extracellular space [142]. 
HA is  degradeted  by  hyaluronidases.  Hyaluronidases  (HYALs)  hydrolyze  the  hexosaminidic 
β(1→4) linkages  between  N-acetyld-  glucosamine  and d-glucuronic  acid residues  in HA. These 
enzymes  also  hydrolyze  β(1→4)  glycosidic  linkages  between  N-acetyl  galactosamine  or  N-
acetylgalactosamine sulfate and glucuronic acid in chondroitin, chondroitin 4- and 6-sulfates, and 
dermatan.  Therefore, HA is easly degradated in vivo.
HA covalently binds to a variety of proteins (HABPs), also referred to as hyaladherins [143]. 
These  include  receptors  such  as  CD44,  RHAMM  (receptor  for  hyaluronan  mediated  motility 
expressed  protein),  and  LYVE-1  (lymphatic  vessel  endothelial  hyaluronan  receptor-1).  Some 
hyaladherins  are  associated  with  cell  membranes,  whereas  others  are  found in  the  extracellular 
matrix. CD44 is the major cell surface HA binding proteins.  Most cells—including stromal cells 
such as fibroblasts and smooth muscle cells, epithelial cells, and immune cells such as neutrophils, 
macrophages,  and  lymphocytes—all  express  CD44  [144].  HA-CD44 interactions,  as  mentioned 
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Figure 8. Structure of hyaluronan. Hyaluronan iscomposed of repeating units of d-glucuronic acid- β(1→3)-N-acetyld-
glucosamine. The disaccharide units are linked by a β(1→4) bond (red ). Two disaccharide units are shown. GlcA, d-
glucuronic acid; GlcNAc, N-acetyld- glucosamine
above, may play an important role in growth, development, cell migration, cell adhesion but also in 
inflammation process.
As showed by Camenish TD et al. HA is involved in heart development during embryogenesis. 
In fact, the targeted deletion of HAS2 gene results in embryonic death at approximately E9.5, with 
extensive abnormalities of the developing cardiovascular system [145]. HA is important also for 
cardiomyocytes, endothelial [145] and mesenchymal stem cells migration [146]. Moreover, HA has 
been  implicated  in  angiogenesis.  It  appears  to  exert  its  biological  effects  through  binding 
interactions with at least two cell surface receptors: CD44 and receptor for HA-mediated motility 
(RHAMM) [147].  Again, the engagement of CD44 with HA induces cyclooxygenase-2 (COX-2), 
generates VEGF, and thus leads to an increase in endothelial cells proliferation [148].
Owing to its distinctive behaviour, versatility and biological properties, HA has been investigated 
by many researchers with a view to its potential use in biomaterials for heart tissue regeneration. 
However,  due to its  poor mechanical  properties,  the use of unmodified HA has been limited to 
viscosurgery applications.  To overcome these limitations,  several  approaches have been taken to 
improve mechanical properties by structural modification of the HA molecule. These have generally 
involved altering the ratio of hydrophobic to hydrophilic substituents on the polymer backbone, or 
the introduction of intermolecular crosslinking. For example, HA has been chemically modified by a 
coupling  reaction  – such  as  esterification  via  its  carboxyl  groups  – with  various  alcohols,  both 
therapeutically  active  and inactive.  This  has  led  to  a  wide  range  of  derivatives  with  enhanced 
processability and mechanical properties in both the dry and the wet state [149].
6. Strategies, challegenges and further directions
The most obvious question to be answered by preclinical studies is which type of cell is the best 
candidate for cardiac therapy [150]. Different cardiac pathologies — for example, acute myocardial 
infarction and chronic ischemic cardiomyopathy — might require different types of stem cell or 
progenitor cell. 
Moreover, a crucial issue in designing more rational cell-based therapy approaches for cardiac 
disease is understanding the mechanisms by which each of the stem-cell or progenitor-cell types 
used can affect myocardial performance [151, 152]. 
Another issue is determining the optimal route of delivery; retention of cells immediately after 
delivery is highly dependent on the delivery strategy. Survival in the inflammatory environment of 
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infarcted myocardium is a challenge common to all types of transplanted cell, as typically 90% of 
the cells  die within a week [151].  A sufficiently large cell  graft  with appropriate  structural  and 
functional properties will be needed. 
Finally,  long-term  electromechanical  stability  and  appropriate  structural  and  functional 
electromechanical integration [153] with host tissue will be essential for cardiac regeneration. 
Therefore,  each  steps  in  cardiac  stem cell  therapy  [Fig.9]  is  important  and  requires  careful 
consideration and better understanding in order to improve the final result: cardiac regeneration.
All these step can be summarized in:
• Stem cell isolation
• Stem cell delivery method
• Survival and proliferation factor
• Electromechanical integration 
• Stability and safety
. 
Moreover,  understanding  cardiomyocyte  development  and  turnover  —  both  in  normal 
development and after injury — will be essential for guiding the development of stem-cell-based 
therapies [154]. 
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Figure 9. True cardiac regeneration with stem cell therapy will require careful consideration at each step, from isolation of the cells to 
their stable and safe long term integration (Figure from Vincent F. M. Segers and Richard T. Lee, Nature 2008)
Defining the factors present in the hostile microenvironment of injured myocardium that limit the 
survival  and  functional  integration  of  transplanted  cells  is  also  crucial.  The  realization  that 
regenerative mechanisms do exist in mammalian myocardium brings into sharp focus the problem of 
defining the barriers that could be preventing regeneration, including the ischemia, inflammation 
and  fibrosis  that  characterize  various  stages  of  infarcted  myocardium  [Fig.10].  This  hostile 
microenvironment might prevent the activation of resident CSCs and thus also reduce the success of 
exogenous cell  therapies. Some components of the inflammatory response might be essential  for 
promoting  angiogenesis  and  progenitor-cell  recruitment,  but  excessive  inflammation  might  also 
prevent  the  recruitment  and  survival  of  progenitor  cells.  Similarly,  some  degree  of  fibrosis  is 
required to prevent myocardial rupture after a myocardial infarction, but dense fibrosis presents a 
formidable physical barrier to regenerating cells. It is likely that no single factor defines the hostile 
microenvironment of injured myocardium [154].
Of course, a major effort by basic researchers is required to better understand all these factors 
affecting cardiac stem cell therapy before application in clinical trials.
 
39
Figure 10.  Mechanism of,  and potential barrier to, cardiac regeneration  (Figure 
from Vincent F. M. Segers and Richard T. Lee, Nature 2008)
EXPERIMENTAL SECTION
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AIM OF THE STUDY
Stem cells offer the opportunity of transplanting a live source for self-regeneration. The isolation 
of  stem and  progenitors  cells  is  now  being  developed  for  many  different  clinical  applications 
including heart failure.  Traditional clinical  therapies such as pharmacological medications,  organ 
transplants and other methods have proved far from effective to full recovery of such patients. 
Stem cell-based therapy, focusing on repairing damaged heart tissue, is a promising option for 
treatment  of  ischemic  diseases.  Several  cell  types  have  been  shown  to  increase  the functional 
recovery of the heart after ischemia, but unfortunately scientists are still far to identify the best cell 
and/or the best cell delivery method.
This  study was  designed to  investigate  the  relevance  of  tissue  engineering  strategies  for  the 
regeneration of the heart following myocardial infarction in animal model. 
At  this  purpose  we  tested  cell  adhesion,  proliferation  and  vitality  of  rat  bone-marrow 
mesenchymal  stem cells  seeded onto a hyaluronan-biopolymer,  HYAFF®11, developed by Fidia 
Advanced  Biopolymer  (FAB  -  s.r.l.,  Abano  Terme,  Italy).  Subsequently,   we  transplanted  the 
scaffold into heterotopic infarcted rat hearts, in order to evaluate the effects of this new strategy for 
cardiac cell delivery. 
Moreover, in order to investigate the fate of endogenous resident cardiac stem cells in animal 
hearts,  I  attended  for  more  than  one  year,  the  Cardiovascular  Research  Institute at  New York 
Medical College, (Valhalla, NY, USA) directed by Doctor Piero Anversa. 
There  I  characterized  the  cardiac  phenotype  of  α-MHC-ODC-transgenic  mice  using  both 
immunohistochemical and biomolecular techniques (see APPENDIX).
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MATERIALS&METHODS
Isolation and culture of rat bone marrow mesenchymal stem cells
Rat  mesenchymal  stem  cells  (rBMSCs)  were  isolated  from  rat  bone  marrow  according  to 
Javazon et al 2001. Bone marrow plugs were extracted from the  femurs of 2-months old Lewis 
syngeneic rats (Harlan, Italy) by inserting a 21-gauge needle into the shaft of the bone and flushing 
the  bone  marrow cavity  with  30  mL of  20% FBS  α-modified  Eagle’s  Medium  (BioWhittaker, 
Walkersville,  MD,  USA)  without  deoxyribonucleosides  and  added  of  100  U/mL 
penicillin/streptomycin  (BioWhittaker,  Walkersville,  MD,  USA)  and  0,1  µg/mL  L-glutamine 
(BioWhittaker,  Walkersville,  MD,  USA).  Marrow plug  suspension  was  dispersed  by  passing  it 
through 70  µm filter  (Falcon,  Franklin Lakes,  NJ,  USA), plated in T-75 culture flask (Sarstedt, 
Nümbrecht, Germany)  and incubated at 37°C, in a 5% CO2  humidified atmosphere. The following 
day, cultered cells were washed twice with PBS in order to remove non-adherent cells then  10% 
FBS α-MEM was added. 
The mesenchymal population was isolated on the basis of its ability to adhere to the culture plate. 
Culture medium was changed every 3-4 days.  At 90% confluence, the cells were trypsinized by 
incubation with 0.25% trypsin-EDTA (Sigma, St. Louis, MO, USA), centrifuged at 1000 rpm for 10 
minutes  and  resuspended  in  10  mL  complete  medium,  counted  manually  in  duplicate  using  a 
Bürker’s  chamber,  and plated  as P1 on 58-cm2 plates  at  densities  of 2000 cells  cm2.  Complete 
medium was replaced every 3–4 days over the 18 to 24-day period of culture.
First-passage rBMSCs were used in all experiments.
Immunological characterization of rBMSCs
For  immunostaining  BMSCs  were  seeded  onto  glass  coverslips  and  fixed  in  4% 
paraformaldehyde at room temperature for 15 minutes and then washed twice with Ca2+ and Mg2+ free 
PBS.  Non-specific  antibody-binding  sites  were  blocked  with  1%  BSA/0.1%  Tween20/PBS 
(blocking  buffer) for  45 min  at  room temperature  following which,  the primary antibodies  anti 
CD90 (Pharmigen, San Diego, CA, USA) 10  µg/mL in blocking buffer, anti CD34, CD45 (Santa 
Cruz Biotechnology,  Santa Cruz, CA, USA) 1:100 in blocking buffer were added and incubated 
overnight at 4° C or 1h at room temperature. Cells were washed 5 min three times in PBS and 
incubated  1  hour  in  FITC-conjugated  or  Cy3-conjugated  anti-mouse  IgG  secondary  antibody 
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(Sigma, St. Louis, MO, USA) at room temperature. The cells were washed 5 min three times in PBS 
and cells’ nuclei labelled with, 4',6-Diamidino-2-phenylindole (DAPI; Sigma, St. Louis, MO, USA) 
15 min at room temperature. After immunofluorescent staining cells were mounted with Vectashield 
mounting medium (Vector Laboratories, Burlingam, CA, USA) on standard glass slides. 
The images were taken using the  IX50 Olympus Fluorescence  microscope  (Olympus,  Tokyo, 
Japan). No significant fluorescent signal was detectable with any of the secondary antibodies alone.
Flow cytometry analysis
Flow cytometry analysis was performed using an Epics Elite (Beckman Coulter, Fullerton, CA, 
USA) flow cytometry equipped with a 15-mW argon ion laser tuned to 488 nm. Green and red 
fluorescences were collected at 525 nm and 605 nm, respectively.
Cells  were  detached  with  a  solution  containing  500  mg/mL  trypsin  and  200  mg/mL  EDTA 
(BioWhittaker,  Walkersville,  MD,  USA),  washed  in  PBS,  and  centrifuged  at  1000 rpm for  10 
minutes. The pellets were resuspended in 3 % paraformaldehyde for 15 minutes at room temperature 
and  then  washed in  PBS.  Non specific  antigens  were  blocked by incubating  the  cells  at  room 
temperature for 1 hour in a solution containing 1% BSA and  0.1% FBS in PBS. Aliquots (2 to 3 x 
105  cells) were incubated with mouse anti CD90 (Pharmigen, San Diego, CA, USA) or rabbit anti 
CD59 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) primary antibodies for 45 minutes at room 
temperature. The cells were washed by centrifugation in PBS, and the pellet was resuspended in 
antimouse  FITC-conjugated  (Sigma,  St  Luis,  MO,  USA)  or  antirabbit  rhodamine-conjugated 
(Sigma, St Luis, MO, USA) secondary antibodies for 20 minutes at room temperature in the dark. 
Primary antibodies were used 1:100 for CD90 and 2 µg/mL for CD59 diluited in blocking buffer.
The cells were then washed in PBS and resuspended in 1 mL PBS for fluorescent- activated cell 
sorting (FACS) analysis. Non specific fluorescence was determined using equal aliquots of the cell 
preparation  that  were  incubated  with  antimouse  FITC-conjugated  or  antirabbit  rhodamine-
conjugated antibodies. 
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Biomaterial 
The  biomaterial  used  in  this  study was  a  hyaluronic  acid  -  based  polymer,  i.e.  HYAFF®11, 
developed by Fidia Advanced Biopolymer – FAB - s.r.l., Abano Terme, Italy. HYAFF®11 is derived 
through the total esterification with benzyl alcohol of the carboxyl groups of glucuronic acid along 
the polymeric backbone of sodium hyaluronate.
The  experiments  have  been  performed  on  a  non-woven  structured  HYAFF®11  construct. 
HYAFF®11 is biocompatible and resorbable and integrates with damaged tissues (Campoccia et al, 
1998). 
HYAFF®11  morphological analysis
Samples from non-woven structured HYAFF®11 were initially examined under an inverted light 
microscope and then processed for scanning (SEM) and transmission (TEM) electron microscopy. 
For SEM the samples were directly mounted on aluminium stubs and then coated with a thin layer 
of gold before examination.  For TEM, both glutaraldehyde fixed and unfixed 2x2 mm3 samples 
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were embedded in Epoxy resin. Before examination, thin section were stained with lead citrate and 
uranyl acetate.
Culturing rBMSCs  on hyaluronan-scaffold
Cells at the first passage were trypsinized at 90% of confluence, resuspended in 0.5 ml  10% α-
MEM medium and counted manually in duplicate using a Bürker’s chamber. Patches of 0.3-0.5 cm2 
of  non-woven structured  HYAFF®11 were pre-treated with complete culture medium for 1 to 3 
hours before seeding. Then  a suspension of 50 μl of cells was seeded at the concentration of 2x106 
cell/cm2 on the upper surface by gently dropping on the medium-wetted scaffolds. The scaffolds 
were left  at 37°C,  in a 5% CO2  humidified atmosphere for 4 hours to allow the cells  to attach. 
Afterwards, 0.5 ml medium was added and further cell culturing was carried out in 24-well plates 
(Sarstedt, Nümbrecht, Germany) at 37°C, in a 5% CO2  humidified atmosphere.
Interaction between rMSCs and HYAFF®11 was investigated on days 1, 3, 7, 14, and 21 using 
appropriate techniques. Cell culture media was changed twice a week. 
At least three scaffolds were analysed for each experimental condition and at each time-point. 
rBMSCs adhesion on HYAFF®11 
The  trypan  blue  exclusion  staining  method  was  used  to  quantify  rBMSC adhesion  onto  the 
biopolymer. rBMSCs were seeded on the scaffold as described above. 
After 24 h, the number of cells bound to the fibres was calculated by subtracting from the known 
number of total seeded cells the amount of cells which adhered to the well bottom and those still 
present in the supernatant, determined by Bürker hemocytometry chamber counting: 
[n° HYAFF®11 adherent cells = n° seeded cells – (n° well-adherent cells + n° suspended cells)].
rBMSC viability and proliferation into HYAFF®11 
rBMSC viability  onto HYAFF®11 was analysed  at  1,  7,  and 14 days  by using the vital  dye 
carboxyfluorescein diacetate, succinimidyl ester (VybrantTM CFDA-SE Cell Tracer Kit, Molecular 
Probes,  Eugene,  Oregon,  USA)  following  the  manufacturer  instructions.  CFDA-SE  is  a  non-
fluorescent dye that passively diffuses into the cytoplasm of cells. Once inside the cell, it is cleaved 
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by intracellular esterases, becoming fluorescent. This highly amine-reactive product then forms dye-
protein  adducts  that  are  retained  by the cells  throughout  their  development.  Moreover  CFSE is 
inherited  equally  by  daughter  cells  after  division,  resulting  in  the  sequential  halving  of  mean 
fluorescence with each generation.
rBMSC  proliferation  was  determined  by  the  (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT; Sigma, St. Louis, MO, USA) assay at day 4, 7, 14 as previously 
reported (Lisignoli et al, 2001). After removing the supernatant, the scaffold was washed with PBS, 
transferred into a new well containing 1 ml of MTT solution (1 mg/ml) and incubated for 3 h at 
37°C in a 5% CO2  humidified atmosphere. The scaffold was then transferred into an eppendorf tube 
containing 1 mL of solubilization solution (0.01 M HCl in isopropanol) and vortexed for 5 min. This 
provoked the release from the scaffold of MTT which was actively reduced by viable cells acquiring 
a yellow colouring. Each sample was centrifuged at 15,000 x g for 5 min and the supernatant was 
read at  595 nm using a multiwell  spectrophotometer  (Victor 2 microplate  reader,  Perkin Elmer, 
Wellesley, MA).
Immunofluorescence detection of CD90 expression
HYAFF®11-rBMSC cultures were fixed at day 21 at room temperature for 24 hours with 10% 
formalin and then embedded in paraffin.  After deparafinization and re-hydration,   samples were 
blocked with 1% BSA dissolved in 0.2% tween-20/PBS and then rinsed three times with PBS. The 
primary antibody monoclonal mouse anti-rat CD90 (Pharmingen, San Diego, CA) was diluted 1:100 
in blocking buffer for 1 h at room temperature and washed three times in PBS. The secondary Cy3-
conjugated  polyclonal  anti-mouse  antibody  (Sigma,  St  Luis,  MO,  USA) was  diluted  1:2000 in 
blocking buffer, incubated 45 min at room temperature and then washed three times in PBS.  Nuclei 
were stained with DAPI (Sigma, St. Louis, MO, USA) diluted 1:1000 for 15 min and washed three 
times  in  PBS.  Cells  were  mounted  with  Vectashield  mounting  medium (Vector  Laboratories, 
Burlingam, CA, USA). The samples were observed with an IX50-Olympus inverted microscopy 
(Olympus, Tokyo, Japan).
Light, transmission and scanning electron microscopy analysis
On day 1, 3, 7, 14 and 21, HYAFF®11-rBMSC cultures were processed for light and electron 
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microscopy. 
For light microscopy (LM), the samples were fixed in formalin and embedded in paraffin; the 
samples were stained with hematoxylin and eosin.  
For TEM, the samples were fixed in 2.5% buffered glutaraldehyde, post-fixed with 1% osmium 
tetroxide and embedded in Epoxy resin; semithin sections were stained with toluidine blue and thin 
sections  with  uranyl  citrate  and  lead  citrate;  the  thin  section  were  observed  in  a  Philips  400T 
transmission electron microscope.
For  SEM, following fixation the samples were dehydrated and critical point dried. The samples 
were mounted on aluminium stubs and then coated with a thin layer  of gold using a sputtering 
device. 
The samples were observed in a Philips 505 scanning electron microscope at 15kV.
Confocal microscopy analysis of CD44 expression
4 µm thick dewaxed histological sections were incubated overnight with anti-CD44 monoclonal 
antibody  (Chemicon,  Temecula,  CA,  USA)  1:100  in  blocking-buffer.  After  washing  in  PBS, 
immunolabelling was carried out by incubating sections for 1 hour with a goat anti-mouse IgG 
Alexa-Fluor-488-conjugate (Molecular Probes, Eugene, Oregon) 1:200 in PBS. The sections were 
finally mounted with a fluorescent mounting medium and analyzed by a LSM 510 confocal laser 
microscopy system (Zeiss, Jena, Germany) which incorporates two lasers (Argon and HeNe).
rBMSC BrdU-labelling and immunofluorescence detection of BrdU
In order to detect the cells after  biopolymer construct transplantation within the heart , cultured 
cells were labelled with the thymidine analogue 5-bromo-2' deoxyuridine (BrdU; Pharmigen, San 
Diego, CA, USA). The cells  were seeded on hyaluron-based scaffold dishes (HYAFF-11®)  of 
0.3-0.5 cm2  area at the density of 2x106 cells/cm2 for 3 weeks and incubated with BrdU 10 µM in 
complete culture medium for 72 h.  
HYAFF®11 –labelled  rBMSC cultures were fixed at day 21 at room temperature for 24 hs with 
10% formalin and then embedded in paraffin. After deparafinization and rehydration,  samples were 
blocked with 1% BSA dissolved in 0.2% tween-20/PBS and then rinsed three times with PBS. DNA 
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was  denatured  by  incubating  sections  in  2N  HCl  for  30  minutes  at  37  °C,  and  then  the  acid  was 
neutralized by immersing sections in 0.1M borate buffer for 2x5 min.  The primary ready-to-use 
monoclonal  mouse  antibody anti-BrdU (BioGenex,  San Ramon,  CA, USA) was incubated  over 
night at 4°C and the following day washed three times in PBS. Unspecific bindings were blocked by 
incubating  the samples with 1%Triton-X100/1M glycine/5% goat serum 1 h at room temperature. 
The secondary Fitch-conjugated polyclonal anti-mouse antibody (Sigma, St Luis, MO, USA) was 
diluted 1:2000 in blocking buffer, incubated 45 min at room temperature and then washed three 
times in PBS.  Nuclei were stained with DAPI (Sigma,  St Luis, MO, USA) diluted 1:1000 for 15 
min  and  washed  three  times  in  PBS. Cover  glasses  were  mounted  with  Vectashield  mounting 
medium (Vector Laboratories, Burlingam, CA, USA) and observed with an IX50-Olympus inverted 
microscope (Olympus, Tokyo, Japan).
Heterotopic heart transplant surgery
The heterotopic heart transplantation [Fig.2] between syngeneic male LEWIS rats (210 to 230 g 
weight  ) was  performed  according  to the  method  of  Lee  et  al  1970.  In  brief,  donor  rats  were 
anesthetized with  Enfluran  via  inhalation.  Cardiac  arrest  was  achieved  by  injecting  cold  (4°C) 
Bretschneider cardioplegic  solution (Custodiol,  Dr.  F.  Ko¨hler  Chemie,  Alsbach-Ha¨hnlein, 
Germany), first in a retrograde manner into the vena cava inferior, then by perfusion of the coronary 
arteries via the aorta. After ligation of vessels, the heart-lungs block was carefully excised, left lung 
excised and infarction induced by left descending coronary artery (LAD) ligation on the bench.  A 
6-0 polypropylene suture was passed through the epicardium layer beneath the LAD 1 to mm from 
its origin, tying the ligature permanently occluding the LAD (Ye et al., 1997). The occlusion was 
confirmed by the appearance of a hypokinetic whitish area. 
Syngeneic Lewis recipients rats were also anesthetized with enfluran via inhalation. The allograft 
was transplanted   by end-to-side anastomosis of the aorta to the abdominal aorta of the recipient. 
Arterial blood from the recipient's abdominal aorta enters the donor left heart via the donor left lung 
and is ejected into the donor ascending aorta by the transplanted left ventricle. Using this model, the 
donor left  ventricle  performs work comparable  to that  of the native  heart.  This  model  is  easily 
reproducible  and can  be  applied  to  various  studies,  including  long-term assessments  of  cardiac 
remodelling,  long-term  efficacy  of  cardiac  preservation,  and  post  transplantation  ventricular 
performance under more physiologic conditions. 
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Two weeks after surgery, abdomen of receiving rats was opened and a pouch of 3 mm2 was made 
in the thickness of the ventricular wall at the level of the post-infarction scar in heterotopic heart. 
The hyaluronic scaffold, previously engineered for 3 weeks with rBMSCs, was introduced into the 
pouch and the myocardial edges sutured with few stitches. Two weeks later, after heterotopic-heart 
functional analysis, rats were sacrificed and heart fixed in 10% formalin for immunohistochemistry 
analysis.
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Fig. 2  Heterotopic heart transplant surgery (1). After ligation of vessels, the heart-lungs block was 
carefully excised, left lung excised (2) and infarction induced by left descending coronary artery 
(LAD) ligation on the bench (3). The allograft was transplanted  by end-to-side anastomosis of the 
aorta to the abdominal aorta of the recipient (4, 5).
Experimental protocol
All the animal  experiments  were performed under the guidelines  on animal  care and welfare 
determined by the Italian Bioethics  Committee.  A total  of 12 male  syngeneic  Lewis   rats  were 
included in this experiment: 6 of them were donors and 6 were recipients. As a control, normal rats 
with no treatment at all were used for the study. In the receiving rat heart, scaffold implantation was 
performed after two weeks from infarcted heart implantation. All rats were kept for 2 weeks after 
HYAFF®11  -rBMSC implantation before sacrifice;   heterotopic  heart  function was evaluated by 
echocardiography immediately after scaffolds transplantation and two weeks later. 
Fig. 3 summarizes the experimental animal protocol
0                             2                            4 wks
0                             2                             4  
Cell/scaffold 
transplantation 
in the cardiac 
scar
Myocardial 
infarction by 
coronary ligation 
and heart 
transplantation 
Cardiac 
scar
Cardiac 
regeneration 
(?)
Histological 
analysis
Functional 
analysis
wks
50
Fig.  3  Experimental  animal protocol.  Time 0: heterotopic  infarcted heart  implantation;  after  2 
weeks: functional analysis and scaffold transplantation; after 4 weeks:  functional analysis and rat 
sacrifice for histological analysis.
M-Mode Echocardiography analysis
M-Mode echocardiography of heterotopic hearts was performed 2 weeks after heterotopic-heart 
transplantation and 2 weeks after scaffold heterotopic-heart implantation just before rats sacrifice. 
After the abdomen was shaved, the rats were placed in dorsal decubitus position. Isoflurane (1-2%) 
was continuously supplied via a mask. In vivo heart function was evaluated by echocardiography 
using a fully digitized Vingmed System Five (GE Vingmed Ultrasound, Horten, Norway) with a 10-
MHz linear array transducer. The transducer was positioned on the left anterior side of the abdomen. 
At first, longitudinal images of the heart were obtained, including the left ventricle, the left atrium, 
the mitral valves and the aorta, followed by the cross-sectional images from the plane of the base to 
the left ventricular apical region. Two-dimensional (2D) images of the left ventricle were obtained 
both in long and short axes. Short axis recordings and M-mode tracings were performed at the level 
of the papillary muscles. All of two-dimensional images, M-mode tracings and Doppler curves were 
recorded on videotape for later analysis. 
Fractional  shortening  (FS),  in  percent,  was  calculated  according  to  the  following  formula: 
LV FS (%) = (LVDd – LVDs)/LVDd x 100
where LVDd is left ventricular diameter in diastole, and LVDs is left ventricular diameter in systole 
according to the M-mode tracing from the cross-sectional view.
All measurements were averaged for 3 consecutive cardiac cycles and were analyzed by an observer 
who was blinded to the treatment status of the animals.
Immunohistochemistry procedure and microscope analysis  
At the experimental  end-time point,  heterotopic  heart  were  rapidly excised,  blocked with an 
injection  of potassium chloride  (2 ml  KCl 15%) in order  to  stop the  heart  in  diastole. Cardiac 
cavities were rinsed with PBS to remove blood and thrombus, then the hearts were fixed with 10% 
formalin for 24 hours. Afterwards, the hearts were cut into 3 pieces apex, middle portion and base, 
before being dehydrated in alcohol at increasing concentration and embedded in paraffin.  Blocks 
were  cut  into  6-µm  sections.  Serial  sections  were  stained  with  haematoxylin/eosin  (H&E)  for 
morphological analysis or used for immunofluorescence analysis. 
The  standard  deparaffinization  protocol  was  used,  tissue  sections  were serially  rehydrated  in 
100%, 95%, 70% ethanol and distilled water. Endogenous peroxidase activity was blocked by 3% 
H2O2 10 min at room temperature and the antigens were retrieved in a microwave for 10 minutes at 
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full power in pH=6.0, 10mM TP citrate solution. Non-specific bindings were blocked with 10% 
serum (goat serum for anti-mouse secondary antibody and sheep serum for anti-rabbit secondary 
antibody)  for  45 minutes.  Then the  slides  were incubated  with  the  following prime  antibodies: 
mouse-monoclonal ready-to-use  anti-BrdU (BioGenex, San Ramon, CA, USA) overnight at 4 °C, 
rabbit polyclonal anti-Cardiac Troponin-I 1:100 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) 
1  hour  at room  temperature.  Afterwards,  the slides  were  incubated  for  45  minutes  at  room 
temperature  with one of the two following secondary antibodies  Fitch-  or  Cy3  anti  mouse  IgG 
(Sigma, St Luis, MO, USA) 1:2000 in blocking buffer. Afterwards, slides were washed 10 min in 
PBS  and  then  mounted  with  Vectashield-with  DAPI  mounting  medium  (Vector  Laboratories, 
Burlingam, CA, USA). 
For  light  microscopy  the  BrdU  visualization  was  performed  using  NovoLinkTM Polymer 
Detection System (Novocastra, New Castle, UK) following the manufacturer instructions.
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RESULTS
Rat-Bone marrow Mesenchymal Stem Cells characterization
In  the  first  part  of  the  study,  we  analyzed  by  immunofluorescence  and  FACS  analysis  the 
immunophenotype of extracted rat bone marrow mesenchymal stem cells (rBMSCs). The results 
show that after 10-12 days of culture expansion on polystyrene surface adherent rBMSCs did not 
express the hematopoietic markers CD34 and CD45, nor a specific mononuclear phagocyte marker 
(MP). On the contrary, a very low positivity to CD59, an Sca-1 homologue, was observed, whereas 
53% of total rBMSC were positive to CD90, a superficial antigen expressed by rBMSCs. CD90 and 
CD59 superficial  antigens  were first  determined by immunofluorescence  and then quantified by 
FACS  analysis.  CD34,  CD45  and  MP  marker  were  determined  only  by  immunofluorescence 
because rBMSCs resulted negative to these antigens. After 11 days from seeding, adherent bone 
marrow cells were mostly positive to CD90, dimly positive to CD59, and completely negative to the 
other tested hematopoietic cell markers [Fig. 4].
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Figure 4.   Cytofluorimetric analysis  of rBMSC for CD90 expression.  rBMSCs were  labelled with primary antimouse CD90 
antibody and FITC-conjugated secondary antibody and then analized by FACS. a) after 8 days  of culturing b) after  11 days  of 
culturing .  
The positivity  to  CD90 antigen  was confirmed by fluorescent  immunocytochemistry analysis 
[Fig. 5].
       
I  nteractions between rBMSCs and a hyaluronan biopolymeric scaffold  
Secondary,  we investigated the interactions between a microfibrous three-dimensional scaffold 
based on hyaluronic acid and rBMSCs using different techniques. The hyaluronan based scaffold 
was chosen because  its  molecule  is  constitutively  present  in  the extracellular  matrix  of  all  soft 
tissues and can be selectively modified in its chemistry to obtain a derived compound potentially 
suited for tissue repair. In this study we used the non-woven structured HYAFF®11 produced by 
Fidia Biopolymers (Abano Terme, Italy). Analysis were performed on cell-untreated or cell-treated 
scaffolds  using  light  microscopy  (LM),  scanning  (SEM)  and  transmission  (TEM)  electron 
microscopy or immunohistochemistry techniques.
HYAFF®11 structural analysis
Samples from non-woven structured HYAFF®11 were initially examined under an inverted light 
microscope  (LM)  and  then  processed  for  scanning  (SEM)  and  transmission  (TEM)  electron 
microscopy. 
At LM the HYAFF®11 scaffold was composed by randomly distributed layers of translucid fibres 
in the micron dimensional range [Fig. 6a]. The scaffold overall morphology was better appreciated 
under  SEM  investigation  [Fig.  6b];  here  the   scaffold  fibres  had  a  solid  appearance  with 
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Figure 5.  Immunofluorescence analisys of rBMSCs for 
CD90 antigen.
Merged  images  :  rBMSCs  labelled  with  primary  mouse 
monoclonal  anti  CD90  antibody  and  FITC-conjugated 
secondary antibody (green); nuclei are stained with DAPI 
(blue).   
interconnected voids among them such that a clear gross porous structure was recognizable;  the 
fibre  diameter  ranged  between  12  to  16  µm  with  an  average  of  15  µm  diameter.  At  higher 
magnification  the  fibre  surface  was  slightly  irregular.  At  TEM  the  fibres  were  moderately 
electrondense and at  higher magnification were composed by a tight  mesh of nanofibrils  which 
bulged in correspondence with the free edge of the fibre surface [Fig. 6c,d]. 
                                    
Analysis of cell adhesion and proliferation in HYAFF®11 
rBMSCs  were  seeded  at  the  concentration  of  2  x  106 cell/cm2 on  the  upper  surface  of  the 
hyaluronan scaffold,  cultured up to 21 days  and then analyzed using appropriate  techniques.  As 
detected by the trypan blue exclusion assay, the rBMSC adhesion on the scaffold was high. 
After 24 hours of rBMSC seeding, the number of cells entrapped in the scaffold was similar to 
the number of cells which had been previously seeded, i.e., 96 ± 0.4% of the overall number of the 
initially seeded cells. As viewed with SEM, rBMSCs adhered on the HYAFF® 11 surface efficiently 
forming extremely thin cell sheets  since early days of culture; at day 1, the cells covered an area of 
about 12 ± 2% of the entire seeded scaffold; cell adhesion on the scaffold steadily increased and 
after 21 days the rBMSCs covered an area of 40 ± 10% [Fig.s 7a,b].          
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Figure 6. HYAFF®-11  morphological analysis. Inverted 
LM (a)  showing  layers  of  translucid  fibres  which  SEM 
reveals having a micron dimensional range (b); at higher 
magnification,  SEM  (c)  shows  that  the  fibre  surface  is 
rough; TEM (d) of an individual fibre composed by a tight 
mesh of nanofibrils bulging at the free border edge. Scale 
bars: a) 100 µm; b) 25 µm; c) 1 µm; d) 20nm.
During  their  growth  in  the  scaffold,  rBMSCs remained  viable  and progressively  proliferated 
during incubation times. To test cell viability and proliferation we used respectively the fluorescein-
derived dye CFDA-SE (carboxyfluorescein-diacetate succinimidyl ester) method and the MTT (3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium  bromide) test.  CFDA  provides  a  simple  and 
sensitive  tool  for  the  analysis  of  the  division  history  of  individual  cells,  MTT  is  a  simple 
colorimetric method  to assay cell proliferation (see Meterial&Methods section for details). 
Results are shown in Figure 8.
      
Morphological analysis of rBMSC interaction with and migration through HYAFF®11 
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Figure 8. rBMSC viability and proliferation into HYAFF® -11  non-woven scaffold. Micrographs (a-c; magnification 10x) show 
representative CFDA staining of rBMSCs at different times of culture onto Hyaff-11®. Proliferation of rMSCs up to 14 days (d) was 
estimated by the MTT assay as described in Materials and Methods. Values are expressed as mean ± S.E.M. (n = 3). One-way 
ANOVA was performed as statistical analysis (p < 0.01), followed by Dunnett's comparison test. *p < 0.05, **p < 0.01 vs. day 4.
Figure 7. Surface analysis of cell adhesion on the scaffold. At day 1 (a), rMSCs cover small areas of the seeded 
scaffold  as thin cell layers,  whereas after  21 days  of culture (b) rMSCs spread over the surface forming large 
confluent cell layers. Scale bars: a, b = 20 µm.
LM showed that rBMSCs were able to migrate throughout the entire thickness of the scaffold. 
After 3 days of culture cells start permeating the inner regions of the scaffold even though rBMSCs 
appeared more  homogeneously distributed in the scaffold thickness  only starting from day 7 of 
culture [Fig. 9a, b]. This finding mimics one of the pivotal “in vivo” properties of hyaluronate that is 
facilitating cell migration.
At day 7 of culture, TEM showed the rBMSCs tightly adhered to the fibres through well-spaced 
focal  contacts,  which are,  as it  is known, specifically involved in the interaction of MSCs with 
extracellular  matrix  (ECM);  nuclear  chromatin  was  finely  dispersed  and  the  cytoplasm rich  in 
dilated cisternae of rough endoplasmic reticulum. After 15 days, a filamentous fibronexus was found 
in  the  free  narrow space  located  between  cell  membrane  and biomaterial  surface;  at  this  time, 
rBMSCs still  had a synthetic  phenotype  and no significant  degenerative changes,  e.g.  vacuoles, 
secondary  lysosomes,  lipid  inclusions,  were  observed.  After  21  days,  autologous  extracellular 
matrix,  including  collagen  fibres  and  proteoglycan  particles  were  found  between  rBMSCs  and 
HYAFF®11 fibres.  A  corresponding  finding  was  seen  at  SEM  where  filamentous  extracellular 
material was observed in close contact with rBMSC plasma membrane. 
Representative results of the rBMSC interaction with HYAFF®11  are illustrated in Figure 10.
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Figure 9. rBMSC migration through HYAFF®-11  fibres.  LM showing rBMSCs migration in the inner 
portions of the scaffold at day 3 (a). At higher magnification (b) cells are spindle and viable. Scale bars: a) 
200 µm; b) 50 µm.
Confocal and immunofluorescence analysis of CD44 and CD90 expression
At day 3, confocal images of rBMSCs cultured on non-woven structured HYAFF®11 showed a 
polarized cell membrane expression of CD44 molecule, the native receptor for hyaluronic acid [Fig. 
11a,c].  The CD44 molecule was preferentially expressed in correspondence with the material-cell 
contact. 
After  21  days,  the  abundance  of  CD90,  a  marker  of  MSC  stemness,  was  not  negatively 
influenced by cell-scaffold interaction showing a homogeneous membranous pattern of expression 
[Fig. 11d,e], suggesting that rBMSC prolonged interaction with the substrate did not modify the 
multipotency of the investigated cell model.
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Figure 10. rBMSC interaction with HYAFF® -11 fibres. TEM of 7 day culture (a, b) showing a rBMSC wrapping a scaffold fibre; 
the arrows indicate regularly-spaced focal contacts. rBMSCs have nuclei with finely dispersed chromatin and numerous cisternae of 
rough endoplasmic reticulum in the cytoplasm (c). After 14 days (d), a distinct fibronexus is seen while connecting the contractile cell 
cytoskeleton with the outer portion of a scaffold fibre. Autologous fibrillary extracellular matrix is seen after 21 days of culture (e, f). 
Scale bars: a) 1 µm; b) and c) 2 µm; d) 0.5 µm; e) 10 µm; f) 1 µm.
In vivo   application of HYAFF ®  11   engineered with rBMSCs  
The in vitro studies showed that the microfibrous nature, the gross porous structure and the three-
dimensional architecture of HYAFF®11 facilitates adhesion, migration, and proliferation of rBMSCs 
as well as the synthesis  and delivery of autologous extracellular  matrix components under static 
culture condition without any chemical induction. 
The high retention rate and viability of the seeded cells, as well as the fine mechanisms of cell 
interaction with the substrate, suggested that such scaffold could be potentially useful in cardiac 
tissue repairing. 
At this purpose we tested the HYAFF®11 engineered with rBMSC in a heterotopic infarcted rat 
heart model. 
Experimental animal model
rBMSCs at first passage were cultured for 21 days on HYAFF®11 before transplantation into the 
infarcted  region  of  a  heterotopic  rat  heart.  For  the  heterotopic  heart  animal  model   we  used 
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Figure 11. Confocal and immunofluorescence microscopy of CD44 and CD90 expression of rBMSCs grown in the scaffold. 
Confocal images of immunohistochemical analysis of CD44 antigen (a-c) in rMSCs at day 3. a) CD44 expression (green); b) phase 
contrast; c) merged image. CD44 expression is polarized in correspondence with the scaffold contact. Scale bars: a, b, c = 10 µm. 
Immunofluorescence detection of CD90 at day 21 (d, e - magnification 20x). d) CD90-related Cy3 fluorescence (red) was extended to 
a large portion of the sample; e) nuclear staining with DAPI (blue) shows the high number of MSCs which are present in the sample.  
In the background the hyaluronan fibres are weakly stained with DAPI
syngeneic Lewis two-months old rats to avoid allograft rejection; half of them were donors, half 
recipients.  In  brief,  hearts  were  excised  from the  donor,  left  descending  coronary  ligation  was 
performed on the bench and the infarcted  heart implanted into the abdomen of recipient rats (see 
Materials&Methods section for more details). We chose this model because the donor left ventricle 
performs  work  comparable  to  that  of  the  native  heart  and  because  this  procedure  is  easily 
reproducible. 
After infarcted heterotopic heart implantation we waited 2 weeks, therefore we measured cardiac 
function by M-Mode echocardiography and we transplanted HYAFF®11-rBMSCs construct into the 
heart infarcted area. Again, two weeks later we measured heterotopic cardiac function, afterwards 
we sacrificed recipient rats and we fixed the heterotopic heart for histological analysis.
The experimental protocol is summarized in Figure 3.
rBMSC labelling
In order to investigate the fate of rBMSCs delivered through HYAFF®11 into the infarcted heart, 
cells  were  labelled  by  incubation  with  bromodeoxyuridine  (BrdU)  10  µM for  72  hours  before 
construct transplantation. BrdU is a thymidine analog that is used in cell proliferation studies. BrdU 
in culture is incorporated into the DNA during DNA synthesis; rBMSCs incorporation of BrdU was 
detected using an anti-BrdU specific antibody by immunocyto- (HYAFF®11-rBMSCs construct) or 
immunohistochemistry (HYAFF®11-rBMSCs construct after heart transplantation) techniques.
BrdU+-cells were detected by both fluorescent and light microscopy [Fig. 12]. 
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Figure 12. BrdU labelled rBMSCs.  Fluorescent and light microscope images of rBMSCs seeded onto HYAFF®11 and incubated 
with BrdU for 72hs. A) nuclei stained with Dapi; B) nuclei labelled with antimouse anti-BrdU primary antibody and Fitch-conjugated 
secondary antibody; C) Brdu+positive cells (dark spots) detected on HYAFF®11 by Novo LinkTMPolymer detection system Kit.
Histological analysis
At the end of the forth week, after cardiac functional analysis, recipient rats were sacrificed and 
heterotopic heart rapidly excised, fixed, embedded in paraffin and used for histological analysis. 
Heart sections were used for morphological studies (stained with H&E),  fluorescent analysis  or 
light microscopy study. 
Heart  structures  observed  by  H&E  staining  had  a  relatively  normal morphology  and  no 
malformations were found. We observed slightly more loose connective tissue containing signs of 
an active neo-vascularization near the infarcted area as compared to non-infarcted hearts [pictures  
not shown]. As shown in Figure 13, the hyaluronan fibres of the transplanted scaffold had not been 
substantially degraded 2 weeks after HYAFF®11-rBMSCs construct heart-implantation and they  are 
surrounded by non-specific inflammatory and giant cells. We expected a non-specific inflammatory 
response  after  scaffold  implantation,  because  it  is  known  that  following  the  implantation  of  a 
biomaterial, an inflammatory process, called Foreign Body Reaction (FBR), could initiate a complex 
series of reactions tending to prevent the ongoing tissue damage, isolate and destroy the foreign 
material and activate the repair process [155]. Anyway, if the inflammatory reaction is limited and 
not  chronic   it  can  be  considered  as  a  normal  response  and  the  material  could  be  considered 
biocompatible [155]. 
           
Analyzing H&E sections in which BrdU-labelled rBMSCs were detected using light microscopy, 
we observed that most of the transplanted cells had migrated to the surrounding infarcted area. 
The BrdU+- cells were especially found close to small-sized vessels or integrated into the wall of 
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Figure 13.  H&E tissue section.  After 2 
weeks  from   construct  implantation 
Hyaff-11® fibres had not been degraded 
even  if  they start  to  be   surrounded  by 
non-specific inflammatory and giant-cells 
(10X magnification). 
bigger vessels [Fig. 14a]. Moreover, we found  BrdU+-cells at the cytoplasmatic level instead of the 
nuclear one. This finding shows that some of the delivered rBMSCs were digested by endogenous 
cells of the recipient rat [Fig. 14b].
 
In order to evaluate if some of the survived transplanted cells might contribute to heart tissue 
regeneration,  we stained some heart  sections  simultaneously with BrdU and cardiac  Troponin I 
(cTnI) antibodies.  cTnI is a later  cytoplasmatic marker of differentiation into cardiac phenotype. 
Fluorescent  microscopy  analysis  showed  that  a  small  number  of  cells,  mainly  found  close  to 
HYAFF®11 fibres or in the periphery of the infarcted region, express both these markers [Fig. 15]. 
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Fugure 14. H&E tissue section. BrdU-labelled rBMSCs (dark spots) are migrated to the surrounding infarcted area. BrdU+ cells are 
detected using a pre-diluited mouse monoclonal anti-BrdU antibody and the  NovoLinkTM Polymer  Detection System. A part of 
delivered rBMSCs is integrated into small-sized vessels (A; 40X magnification) and a part is digested by haematic rat-recipient cells 
(B; 40X magnification).
Figure 15. Immunofluorescence analysis of heart sections. Rapresentative image of rBMSCs  positive for both markers BrdU and 
cTnI two weeks after construct implantation. A) Nuclei stained with DAPI, blue; B) Nuclaer BrdU labelling, green; C) cytoplasmatic 
positivity to cTnI, red 
 This  result  indicates  that  rBMSCs delivered  into  the  infarcted  region  through a  hyaluronan 
scaffold preserve the ability to transdifferentiate into cardiomyocytes.
Functional analysis
Functional analysis of infarcted heterotopic hearts were performed by M-Mode echocardiography 
2 weeks after heart implantation, but before HYAFF®11-rBMSCs transplantation, and 2 weeks later 
the second surgery, before rat sacrifices (see Material&Methods section for more details). 
Analyzing the M-mode images emerged that scar tissue was moderated in the engrafted region 
and the thickness of the corresponding ventricular wall was comparable to that of the non-infarcted 
remote area. 
Posterior wall (PW) thickening, as well as fiber elongation and intra ventricular septum (IVS) 
thickening, are index of cardiac hypertrophy. As shown in Figure 16, IVS and left ventricular PW 
thickening  in  heterotopic  hearts  after  HYAFF®11-rBMSCs  transplantation  are  similar,  or  even 
slightly decreased, if compared to the same parameters measured before construct transplantation. 
These data suggest that the treatment of infarcted heart with MSCs delivered through a biopolymeric 
support  might  contribute  to  avoid  the  wall  thickening  typical  of  post-infarction  left  ventricular 
remodelling.
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Figure  16.  Heterotopic  Heart  Wall  Thickness  before  and  after  HYAFF®11-rBMSCs 
construct heart-implantation. d IVS = diastolic  Intra Ventricular Septum; s IVS = systolic 
Intra Ventricular Septum; pre = before implantation; post = after implantation
Again,  the  left  ventricular  shortening  fraction,  evaluated  by M-Mode echocardiography,  was 
found increased when compared to that measured just before construct transplantation [Fig. 17]. The 
shortening fraction is a slightly different way of measuring left ventricle performance. Instead of 
measuring and ratioing blood volumes, the shortening fraction measures and ratios the change in the 
diameter  of  the  left  ventricle  between  the  contracted  and  relaxed  states. An  increase  in  the 
shortening fraction indicates improvement of cardiac function.
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Moreover, there is no evidence of an increase in LV volumes and dimensions in treated 
heterotopic rat hearts.
Thus, taken together, all these results indicate that inserting a cell engineered-scaffold into the 
infarcted region could favourably affect the heart disfunction consequent to MI.
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Figure  17.  Fractional  Shortening  evaluatred by  M-Mode echocardiography.  FS  in  percent,  was  calculated  according  to  the 
following formula:  LV SF% =  (LVDd – LVDs)/LVDd x 100 ;   LVDd = Left  Ventricular Diameter in diastole; LVDs =  Left 
Ventricular  Diameter  in  systole;  Pre   =  before  scaffold  transplantation;  Post  =  after  scaffold  transplantation;  FS % = Fractional 
Shortening x100. One-tailed Student’s T test , paired data was performed as statistical analysis (p < 0.05)
DISCUSSION
In this thesis, it has been studied a new strategy for cell delivery for the regeneration of the heart 
in a rat model of myocardial infarction: the tissue-engineering therapy. 
At this  purpose we used HYAFF®11 as hyaluronan biopolymeric  scaffold. It  is a biomaterial 
derived  from  the  esterification  of  native  hyaluronan,  which  is  an  abundant  non-sulfated 
glycosaminoglycan component of synovial fluid and extracellular matrices ubiquitous in the body. 
In  appropriate  experimental  settings  HYAFF®11 scaffolds  have demonstrated  to  have properties 
which are interesting for the field of tissue engineering. In fact, HYAFF®11 is biocompatible [156], 
biodegradable [157, 158] and it promotes the adhesion and growth of several cytotypes, including 
keratynocytes [159], endothelial cells [157, 160] and chondrocytes [161,162].
The possibility of combining such biological  properties of HYAFF®11 with those offered by 
multipotent stem cells has been investigated by others with the aim at improving cartilage repair 
[158, 162, 163].
In the present study, first we studied the basic abilities of HYAFF®11 on facilitating the adhesion, 
migration and proliferation of rBMSCs, and then we evaluated the in vivo effects of the construct 
HYAFF®11-rBMSCs implanted into the infarcted area of heterotopic rat hearts.  
The  plain  morphological  analysis  of  the  non-woven  HYAFF®11  scaffold  confirms  its 
microfibrous nature and gross porous structure [Fig. 6 a,b]. The presence of a rough surface [Fig. 
6d] dramatically expands the sites of possible chemical interactions between cells and substrate; this 
characteristic could contribute to early effective cell adhesion on HYAFF®11 surface as documented 
by both SEM and TEM analysis [Fig.7 a,b]. Coherently with this view, the rBMSC retention in the 
substrate was high at day 1 and the number of rBMSCs entrapped within HYAFF®11 was found to 
be comparable to the number of the originally seeded cells by using the trypan blue exclusion stain 
method. 
No significant  cell  loss  and/or  degeneration  was found up to  21 days  of  cell  culture  on the 
substrate as detected by CFDA assay [Fig.8]  and LM. Moreover, MTT analysis demonstrated that 
rBMSCs proliferated steadily during culture conditions [Fig.8] and SEM revealed a subconfluent 
surface monolayer at the end of culture condition. As a logical consequence, the interaction between 
rBMSCs  and  HYAFF®11  was  functional  and  this  was  also  supported  by  the  development  of 
fibronexus,  a  distinct  ultrastructural  structure  which  documents  anchorage  of  cell  contractile 
cytoskeleton to extracellular matrix components [164].
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The HYAFF®11 three-dimensional architecture could be essential in facilitating the migration of 
the seeded rBMSCs within its entire thickness. Accordingly,  starting 3 days after the initial  cell 
seeding, we found cells permeating the innermost region of the scaffold [Fig. 9 a,b].
It is generally accepted that cells attach and organize better around fibres with diameters smaller 
than the diameter of cells [165]. However, the present study demonstrates that even the microfibres 
of HYAFF®11 provides adequate anchorage for cell adhesion. SEM analysis clearly evidenced that 
rBMSCs firmly  adhered  on  the  substrate  as  thin  sheets  thus  recovering  their  phenotypic  shape 
rapidly and,  more importantly,  TEM revealed that  the adhesion was achieved through regularly 
spaced adhesion structures, namely focal contacts, which are specifically involved in the interaction 
of  MSCs  with  extracellular  matrix  (ECM) [Fig.10].  Focal  contacts  represent  the  ultrastructural 
mirror  of  a  complex,  highly  regulated  process,  where  integrins  in  the  plasma  membrane  are 
clustered with other molecules pushing cells toward many adhesion-mediated signalling pathways. 
Schematically, many fundamental cellular functions including motility, proliferation, differentiation, 
and apoptosis are regulated through cell – ECM interactions [166].
 Also,  an  additional  finding  supporting  a  functional  interaction  is  the  confocal  microscopy 
demonstration that the CD44 molecule, the native receptor for hyaluronan acid, was preferentially 
expressed in correspondence with the material-cell contact [Fig.11 a,b,c]. 
An additional point of interest is that the rBMSC growth on the HYAFF®11 was accompanied by 
ultrastructural documentation of expanded protein synthesis and late autologous extracellular matrix 
production.  TEM analysis  of early cultures  showed that  rBMSCs had euchromatinic  nuclei  and 
numerous rough endoplasmic reticulum cisternae in the cytoplasm; at day 21 SEM revealed distinct 
meshworks of extracellular fibrils which TEM demonstrated to be fibrillar collagen admixed with 
small proteoglycan particles [Fig.10]. 
In vivo hyaluronan surrounds migrating and proliferating cells and, expecially in the embryonic 
tissues, facilitates cell differentiation according to their orchestrated destiny. In the present study this 
ability  has  not  been  investigated;  however  human  MSC  chondrogenesis  in  a  similar  polymer 
scaffold was well induced by 20 ng/ml of TGFß1 [167] and consequently a cardiac or endothelial 
differentiation potential can be expected also in our model whether appropriate growth factors are 
utilized. Herein was found that the CD90 surface antigen, a stemness molecule which belongs to the 
basic phenotype of mesenchymal stem cell, was retained up to the end of the culture condition [Fig.
11 d,e], thus suggesting that rBMSC prolonged interaction with the substrate did not modify the 
multipotency of the investigated cell model.
66
The high retention rate and viability of the seeded cells, as well as the fine mechanisms of cell 
interaction with the substrate, suggested that such scaffold could be potentially useful in cardiac 
tissue repairing, thus we tested the HYAFF®11 engineered with rBMSC in a heterotopic infarcted rat 
heart model. At this purpose we transplanted the HYAFF®11-rBMSCs in the infarcted region of a 
heterotopic rat heart and after two weeks we performed functional and histological analysis.
Our results showed that after two weeks the HYAFF®11 fibres have not been degradated but they 
are surrounded by inflammatory cells [Fig. 13]. Hyaluronan-scaffold activates innate alloimmune 
responses acting as a foreign body (Foreign Body Reaction, FBR). Anyway, if the immuno-response 
is  limited  and  not  excessive,  it  might  contribute  to  scar  digestion  and  consequently  tissue 
regeneration.  Improving  our  understanding  of  the  nature  of  the  immuno-reaction  in  tissue-
engineering strategy may lead to improve therapeutics in heart tissue repearing. 
By light and fluorescent microscopy analysis we found that transplanted rBMSCs are still present 
in the heart tissue but they are not close to HYAFF®11 fibres as we expected according to the  in  
vitro studies. In fact, most of the trasplanted cells were especially found close to the vessels [Fig.14] 
in the periphery of scar tissue area or migrated in the viable myocardium. Only a very few cells were 
found close to HYAFF®11 fibres; some of them were differentiating into cardiomyocytes, as showed 
by  the  expression  of  cardiac  markers  such  as  cTnI  [Fig.  15].  We are  not  able  to  explain  this 
phenomenon  but  we can  hypothesized  that  cell  migrate  in  the  sourranding  area  because  of  the 
inflammatory process.
Finally, analyzing functional analysis emerged that there was no IVS or PW thicknening in the 
treated infarcted hearts [Fig. 16] and even the shortening fraction parameter was slightly increased 
[Fig.  17]  two  weeks  after  HYAFF®11-rBMSCs  transplantation.  These  results  indicate  that 
trasplanting a hyaluronan biopolymer engineered with MSCs into the infarcted area could attenuate 
the cardiac disfunction and LV remodelling subsequent to myocardial infarction.
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CONCLUSION
The HYAFF®11 non-woven scaffold has many characteristics which makes it attractive for tissue 
engineering. 
In the present study we have demonstrated that HYAFF®11 facilitates adhesion, migration, and 
proliferation of rBMSCs as well as the synthesis and delivery of autologous extracellular  matrix 
components under static culture condition without any chemical induction. The high retention rate 
and viability of the seeded cells, as well as the fine mechanisms of cell interaction with the substrate, 
suggest that such scaffold could be potentially used for post-infarction cardiac regeneration. 
In fact, the in vivo results indicate  that the treatment of infarcted rat hearts with MSCs delivered 
through a  biopolymeric  support  might  contribute  to attenuate  the  progression  of  pathologic  LV 
remodelling  and  that  post-infarction  myocardial  function  could  be  favourably  affected  by  the 
grafting of MSCs delivered through a hyaluron-based scaffold.
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APPENDIX
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I spent the first year of my PhD course attending the laboratories of the Cardiovascular Research 
Institute at New York Medical College in Valhalla (New York, USA), directed by Doctor Piero 
Anversa.
 Piero Anversa, professor of medicine and director of the Cardiovascular Research Institute,  is a 
well-known cardiovascular researcher who has made landmark discoveries in the pathophysiological 
mechanisms of heart disease. Dr. Anversa’s work on heart failure is reshaping our understanding of 
myocardial  growth and death by providing evidence that  the heart  has its  own adult  stem cells 
capable of regenerating heart muscle tissue following a coronary event [17]. Under the guide of this 
brilliant scientist I started learning about stem cells and I started working into this interesting field. 
During that period I studied proliferation and cell death of cardiomyocytes (CMs) and resident 
cardiac stem cells (CSCs) in a transgenic animal model. I characterized the phenotype of cardiac 
cells of transgenic mice overexpressing, at cardiac level, ornithinedecarboxylase (ODC), the first 
and potential rate-limiting enzyme of polyamines biosynthesis. Polyamines (putrescine, spermidine 
and spermine) are aliphatic polycations essential for the maintenance of cell growth, survival and for 
macromolecular biosynthesis. They exert them role by interacting with nucleic acids, proteins and 
membranes through ionic interaction. Polyamines are involved in many cellular functions including 
gene expression, transcription, signal transduction, cell growth, cell cycle regulation, proliferation, 
cell attachment, cell migration and cell signalling. Consistent with their metabolic and biological 
features, polyamines can be potential targets for multiple intervention also in stem cell manipulation. 
The overexpression of ODC in the heart tissue, as shown by Shantz LM et al [168], leads to an 
increase in intracellular polyamines level and to a slight cardiac hypertrophy. It is known that agents 
responsible of cardiac hypertrophy activate ODC enzyme, thus polyamines biosynthesis, at cardiac 
level.  In fact,  increased polyamine  concentrations  were found in the ventricular  myocardium of 
animal  subjected  to  protocols  known  to  induce  cardiac  hypertrophy,  including  aortic  stenosis, 
intense muscle exercise or treatment with β-adrenergic agonist (ODC inducers).
The aim of my work was, first, to evaluate the cardiac hypertrophy level in ODC-trangenic mice 
and secondarily  to try of  clarifying  if  it  could exist  a  relationship  between polyamines-induced 
cardiac hypertrophy and cardiomyocytes hyperplasia and death and/or resident CSCs proliferation 
and differentiation.
For  developing  this  research  I  used  different  techniques  that  were  very  useful  also  for  my 
subsequently studies in tissue-engineering therapy illustrated in the first part of my thesis; some of 
them are described below.
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TECHNIQUES
Mouse heart perfusion: Cardiomyocytes and Small Cell isolation
Two-months  old ODC-transgenic  and wild  type  mice  were injected  with 200 uL of  heparin 
solution  20  minutes  before  sacrifice.  Immediately  after  they  were  anesthetized  with  CHCl3 
(200-300uL/100g Body Weight); chest was opened and heart incannulated from the aorta. Heart was 
perfused 1 minute in Langerdoff System with Basic Buffer (Minimal eagle’s essential medium, 0.7 
g  HEPES,  0.3  g  Glutamine,  1.25  g  Taurine,  20  units  Insuline,  5  mL  Pen-Strep,  pH  7.2-7.3). 
Afterwards, Basic Buffer was removed and heart was perfused 10 minutes with Collagen Solution 
(50 mg Collagenase TypeII in 50 mL of BASIC BUFFER, 25 nM of CaCl2). Then it was put in a 
dish with Incubation Buffer (100 ml Basic Buffer, 0.5 g BSA, 60 uL CaCl2 0.5 M, pH 7.2-7.3), 
sminced  with  forceps  and  centrifuged  1  minute  at  100g.  Surnatant  containing  the  Small  Cells 
fraction was collected in a Falcon and the pellet, cardiomyocytes fraction, was washed with IB and 
centrifuge again 1 minute at 100g.
Cardiomyocytes culture
Two dishes 30 mm for each digested heart were coated with laminin 50 uL/mL PBS and used for 
cardiomyocytes colture. Cardiomyocytes were resuspended in IB seeded in laminin-coated dishes 
and incubated at 37°C, in a 5% CO2 humidified atmosphere until they were attached to the bottom. 
Then medium was changed and cardiomyocytes kept in colture. For immunohistochemical analysis 
or  cardiomyocytes  measurement  1/3 of  resuspended cardiomyocytes   was  put  in  1  mL of  10% 
formaline .
Small Cell isolation and selection of ckit+  (CD117) cells 
The surnatant from cardiomyocytes isolation was filtered with 40 um filter and centrifuged at 
1800rpm  for 10 minutes. The pellet was resuspended in 80 uL PBS/BSA/EDTA for MACS® cell 
sorting (Miltenyi  Biotec)  and 20 uL of CD117-micro Beads for each sample were added. Then 
samples were mixed at 4°C for 15-20 minutes. Afterwards, cell suspension containing CD117+ cell 
magnetically labelled with CD117 microbeads was loaded on a coloumn which was placed in the 
magnetic field of MACS® Separator. The magnetically labelled cells were retained on the coloumn 
while the unlabelled cells run throughout. After removal of the coloumn from the magnetic field, the 
magnetically retained  CD117+ cell were eluated as the positevely selected cell fraction.
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Mice BrdU injection
In order to evaluate CSCs or cardiomyocytes  proliferation,  all mice used for the experiments 
were injected with 200 uL of BrdU solution (50 mg/10 mL PBS) twice a day for one week before 
sacrifice. 
Immunohistochemical analysis
ODC-transgenic and wild type mouse hearts were arrested in diastole by  injection of potassium 
chloride (2 ml KCl 15%) and fixed in formaline 10% for 24 hours. Afterwards, the hearts were cut 
into  3  pieces  apex,  middle  portion  and  base,  before  being  dehydrated  in  alcohol  at  increasing 
concentration and embedded in paraffin.  Blocks were cut into 6-µm sections. Serial sections were 
stained with haematoxylin/eosin (H&E) for morphological analysis or used for immunofluorescence 
analysis. The standard deparaffinization protocol was used, tissue sections were serially rehydrated 
in 100%, 95%, 70% ethanol and distilled water. Antigens were retrieved in a microwave for 10 
minutes at full power in pH=6.0, 10 mM TP citrate solution. Non-specific bindings were blocked 
with 10% donkey serum for 45 minutes. Then the slides were incubated with the following primary 
antibodies:  mouse-monoclonal anti-BrdU  (from  BD  bioscience-kit)  overnight  at  4°C,  mouse 
monoclonal anti-CD117 (Dako Cytomation) diluted 1:20 in PBS 2 hours at 37°C, rabbit polyclonal 
anti-Ki67 (Pharmigen) 1:300 in PBS Over Night at 4°C.  Afterwards, the slides were incubated for 
45 minutes at room temperature with one of the two following secondary antibodies Fitch- or Tritc- 
anti-mouse or anti-rabbit IgG (Sigma, St Luis, MO, USA) 1:2000 in blocking buffer. Then slides 
were washed 10 minutes in PBS and then mounted with Vectashield-with DAPI mounting medium 
(Vector Laboratories, Burlingam, CA, USA).
For apotosis detection was used the apoptosis kit from BD-Bioscience (Clonech-ApoAlert DNA 
Fragmentation Assay Kit) following the manufacturer instruction.
 The results are rapresentative of the measurement of 20 sections for each animal heart; 6 mice 
for  each  group  were  used.  The  results  are  expressed  in  percent  of  the  total  number  of 
cardiomyocytes for heart section. 
The total number of CM per section was calculated with the following formula: 
CM/mm2 * Section area
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Functional and anatomical measurements
Before mice sacrifice anatomical and functional heart parameters were measured. The functional 
parameters  were taken using the Millar's procedure [169]. Mice were anaesthetized with chloral 
hydrate 400 mg/kg body weight, intraperitoneally, and the right carotid artery was cannulated with a 
microtip pressure transducer (model SPR-671; Millar) for the measurements of LV pressures, and 
LV +dP/dt and LV- dP/dt in the closed-chest preparation.
Cardiomyocytes density and otal number of cardiomyocytes
For the cardiomyocytes density measurement pictures of the H&E heart sections were taken and 
sections area were measured using the IMAGE PRO program. Then, ten pictures for each sample 
with at least 3 nuclei for the measurements of nuclear length were taken.
Cardiomyocytes density (CMs Density) was calculated with following formula:
CMs DENSITY in mm3 =  myocytes in mm2/nuclear length *1000
The total number of cardiomyocytes was calculated with the following formula: 
CMs Density*Heart Volume 
(Heart Volume = Heart weight/1,06)
73
RESULTS and DISCUSSION
The experiments described in the present study use a transgenic approach to examine the effects 
of overexpression of ODC in the heart. At this purpose I used ODC-transgenic mice kindly provided 
by Dr. Anthony Pegg’s laboratory from Hershey Medical Center (Hershey, PA, USA). 
Directed  overexpression  of  ODC to  the  heart  is  accomplished  through  the  use  of  the  well-
characterized α-myosin heavy-chain (α-MHC) promoter. The use of this promoter allows expression 
of ODC in both the atria and ventricles, but not in other organs, of transgenic animals throughout 
adult  life.   The  measures  of  ODC expression  and cardiac  polyamines  level  were  performed  by 
Shantz LM et al  [168].
In  order  to  evaluate  if  the  overexpression  of  the  ODC protein  into  the  heart  tissue  and the 
subsequently  increase  in  polyamines  level  lead  to  cardiac  hypertrophy  and/or  heart  failure 
anatomical and left ventricular functional analysis were performed.
                    
As shown in Figure 18, the anatomical results indicate that while free wall (FW) and septum 
thickness are similar comparing wild type to transgenic mice, the chamber diameter and volume of 
ODC-overexpressing  mice  are  16%  and  41%  higher  than  the  same  parameters  of  wild  type 
respectively.   Moreover, the diastolic wall stress both of FW and septum of transgenic mice are 
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Figure 18. Anatomical analysis. In the graphs are compared the anatomical heart measurement of wild type and ODC transgenic 
mice. All data are representative of 6 animals for each group. 
three times higher then wild type. An increase in these latter parameters indicates a developed mild 
cardiac hypertrophy in the ODC-transgenic mice. For evaluating if cardiac hypertrophy is associated 
to heart failure, hemodynamic parameters were measured before animal death.
The results  indicate  that  in  comparison  with  wild  type  mice,  the  transgenic  group exhibited 
indices of a slight cardiac insufficiency.  In fact in ODC mice left ventricular (LV) end-diastolic 
pressure (LVEDP) was 47% higher, and developed pressure (LVDevP), LV + dP/dt and LV - dP/dt 
were 6%, 11% and 10%  respectively lower than wild type parameters [Fig. 19]. 
These observations indicate that overexpression of ODC in the heart can be itself sufficient to 
cause an obvious hypertrophic phenotype that could lead to heart failure. 
It  is  widely  agreed  that  cardiac  hypertrophy  occurs  to  preserve  normal  cardiac  function  in 
response to different stimulus as hemodynamic overload, adrenergic stimulus or whatever could lead 
to  heart  failure.  For  many  years,  the  lateral  expansion  of  pre-existing  myocytes  has  been 
considered to be the only cellular process available for the augmentation of wall width, which tends 
to normalize the higher peak systolic wall stress.  More recently,  hyperplasia of muscle cells has 
been suggested to represent an additional important component of the response of the myocardium 
in  humans  [170,171].  Myocyte  proliferation  has  been  proposed  to  characterize  the  phase  of 
transition  from compensated  physiological  hypertrophy to  cardiac  dysfunction and overt  failure 
[170]. 
Thus, considering the notion that myocyte cellular hyperplasia could be a significant component 
of the growth mechanism of the diseased heart, and considering that polyamines are involved in the 
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Figure 19. Hemodynamic measurement by Millar’s procedure.  LVEDP = Left Ventricular End Diastolic Pressure; LVDevP = 
Left  Ventricular  Developed  Pressure;  LV -dP/dT =  rate  of  pressure  decay;   LV +dP/dt  =  rate  of  pressure  rise.  All  data  are 
representative of 9 animals for each group.
regulation of cell proliferation, I tried to clarify if, in the ODC-overexpressing mice  hypertrophy, 
this mechanism could be involved. 
At this purpose I performed immunohistochemical analysis evaluating proliferation markers such 
as Ki67 and BrdU [Fig. 20]. Ki67 is a protein strictly associated with cell proliferation. The fact that 
the Ki67 protein is present during all active phases of the cell cycle (G1, S, G2, and   mitosis), but is 
absent from resting cells (G0), makes it an excellent marker for determining the  so-called growth 
fraction of a given cell population. BrdU  (bromodeoxyuridine) is a synthetic    nucleoside which is 
an analogue of thymidine. It can be incorporated into the newly synthesized DNA of      replicanting 
cells (during the S phase of the cell cycle), substituting for thymidine during DNA    replication. An-
tibodies specific for BrdU can then be used to detect the incorporated chemical, thus indicating cell 
that were actively replicating their DNA. At this purpose, I injected all mice used in the experiments 
with a BrdU solution twice a day for one week.
The immunohistochemical analysis indicates that CMs proliferation is very low both in transgen-
ic and wild type mice and that there is no significant difference between the two compared animal 
groups [Fig.20].
Considering that polyamines could regulate programmed cell death inhibiting or favouring cell 
apoptosis in consequence to different stimuli, I hypothesized that it would be a difference in CMs 
cell  death between wild type and transgenic  mice.  For evaluating CMs apoptosis  I performed a 
Tunel. 
The  results  show  that  the  cardiomyocyte  programmed  cell  death  is  very  low  in  both  the 
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Figure 20. Fluorescent immunohistochemical analysis.  Heart sections were stained for proliferation markers such as BrdU and 
Ki67 using appropriate primary  and secondary antibody . The results are rapresentative of the measurement of 20 sections for each 
animal heart; 6 mice for each group were used. Results are expressed in percent of the total number of cardiomyocytes of the heart 
section  calculated with the following formula: CM/mm2 * Section area.
experimental group and the difference between wild type and ODC-overexpressing mice is not so 
high to justify a major number of CMs in the transgenic group [Fig.21].
Thus, all the results collected until now indicate that the cardiac hypertrophy manifested in the 
ODC-transgenic mice is not a consequence of a cardiomyocytes hyperplasia as I hypothesized, but it 
is much probably due to an increase in  cardiomyocytes size (CMs hypertrophy).
To  confirm  this  new  hypothesis  I  measured  cardiomyocytes  density  and  the  total  number  of 
cardiomyocytes both in wild type and transgenic mice hearts.  As shown in the graphs below [Fig.
22],  both  cardiomyocytes  density  and  total  number  of  cardiomyocytes  are  lower  in  ODC-
overexpressing mice than in wild type. Thus, these results confirm that in our animal model the 
manifested cardiac hypertrophy is not dependent by an increase of cardiomyocytes number but by 
an  increase  in  their  cell  size.  Thus,  ODC  overexpression  at  cardiac  level  is  responsible  of 
cardiomyocytes hypertrophy but not of cardiomyocytes hyperplasia. 
Considering that all the mice used in these experiments are young mice (two-months old mice) 
and considering that the transgenic type manifests cardiac hypertrophy and heart failure, we could 
conclude that the overexpression of ODC protein within the heart tissue might lead to a precocious 
heart aging. Of course more experiments are necessary to confirm this hypothesis and to understand 
the  right  mechanism  by  which  a  high  level  of  polyamines   induces  this  cardio-  pathological 
phenotype.
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Figure 21.  Apoptosis  immunohistochemical  analysis.   Heart  sections were  used to  perfome a Tunel  test  using the  Clonech-
ApoAlert DNA Fragmentation Assay Kit visualized by fluorescent microscopy. The results are rapresentative of the measurement of 
20 sections for each animal heart; 6 mice for each group were used. The results are expressed in percent of the total number of 
cardiomyocytes of the heart section calculated with the following formula: CM/mm2 * Section area.
              
The recently discovery of resident cardiac stem cells (CSCs) introduced a new concept  according 
to which the myocardial aging could be a stem cell problem [172]. Aging could affect the growth 
and differentiation potential of CSCs interfering not only with their ability to sustain physiological 
cell turnover but also with their capacity to adapt to an incoming heart failure. 
In  accordance  to  this  notion  and  considering  that  polyamines  regulate  cell  cycle  and  cell 
proliferation, I investigate if the ODC overexpression and the consequent increased in polyamines 
level  within  the  heart  could  affect  the  proliferation  (cell  number)  of  resident  cardiac  stem cell 
identified as ckit+ cells.
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Figure 22.  Cardiomyocytes  density and total number of cardiomyocytes.  Cardiomyocytes  density was  calculated using the 
following formula: CMs DENSITY in mm3 = myocytes  in mm2/nuclear length *1000; the total number of cardiomyocytes  was 
calculated with the following formula: CMs Density*Heart Volume. All the data are representative of  6 animals for each group. 
Two-tailed Student’s T test , unpaired data was performed as statistical analysis (p < 0.05)
Figure  23.  Fluorescent  immunohistochemical  analysis.  Heart  sections  were  stained  for  ckit  using  an  anti  CD117  primary 
antibody and an appropriate FITC conjugate secondary antibody. The results are rapresentative of the measurement of 20 sections 
for each animal heart; 6 mice for each group were used. Results are expressed in percent of the total number of cardiomyocytes of 
the heart section  calculated with the following formula: CM/mm2 * Section area.
The immunohistochemical analysis, reported in the Figure 23, shows that there is no evidence of a 
difference in the number of resident ckit+ cardiac stem cells comparing ODC-transgenic mice to the 
wild type. Thus, this indicates that the high level of polyamines doesn't effect the proliferation of the 
ckit population of resident cardiac stem cells. Anyway, this result doesn't exclude that high level of 
polyamines could affect ckit-CSCs differentiation or the proliferation and/or differentiation of the 
other populations of resident CSCs, such as Sca-1+, Abcg2+, and isl1+ cardiac stem cells. 
CONCLUSION
In  the  present  study  I  characterized  the  cardiac  phenotype  of  young  ODC-transgenic  mice 
overexpressing  ODC at  cardiac  level.  By  anatomical  and  functional  analysis  emerged  that  the 
transgenic mice manifested a mild cardiac hypertrophy correlated to a slight cardiac insufficiency 
[Fig. 18, 19]. I tried to clarify if the high level of polyamines, consequent to the increased ODC 
protein expression within the heart, was correlated to this pathological phenotype considering the 
important role of these polycations in regulating cell proliferation and cell cycle. The results indicate 
that the manifested transgenic-mice hypertrophy was due to a simply increase in cell size and not to 
a cardiomyocytes proliferation [Fig. 20, 21, 22]. This phenomenon could be justified as a precocious 
aging  process  of  the  myocardial  tissue  induced  by  polyamines.  Because  of  the  new  concept 
according to which myocardial  aging is a stem cell problem, I evaluated if the number of ckit+-
cardiac stem cell was affected by the increased in polyamines concentration. According to the result 
[Fig.23],  it  can be excluded that  ODC-overexpression at  cardiac  level  influences  the ckit-CSCs 
number and proliferation, but it cannot be excluded that an increase in polyamines level could affect 
the proliferation or differentiation of Sca-1+, Abcg2+, and isl1+ cardiac stem cells population. 
Thus,  more  experiments  have  to  be  performed  to  elucidate  the  relationship  that  could  exist 
between polyamines and cardiac hypertrophy.
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